

B1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 September 2001 (20.09.2001)

PCT

(10) International Publication Number
WO 01/68603 A2(51) International Patent Classification⁷: **C07D 209/52,**
A61K 31/403, A61P 3/04, 3/06, 3/10

David, A. [US/US]; 3 Easton Court, Lawrenceville, NJ 08648 (US).

(21) International Application Number: **PCT/US01/07151**(74) Agents: **ALGIERI, Aldo, A. et al.**; Bristol-Myers Squibb Co., P.O. Box 4000, Lawrenceville-Princeton Rd., Princeton, NJ 08543 (US).

(22) International Filing Date: 5 March 2001 (05.03.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:(30) Priority Data:
60/188,555 10 March 2000 (10.03.2000) US

— without international search report and to be republished upon receipt of that report


(71) Applicant (*for all designated States except US*): **BRISTOL-MYERS SQUIBB CO.** [US/US]; P.O. Box 4000, Lawrenceville-Princeton Road, Princeton, NJ 08543 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ROBL, Jeffrey, A.** [US/US]; 7 Tulip Drive, Newtown, PA 18940 (US). **SULSKY, Richard, B.** [US/US]; 2 Coventry Square, West Trenton, NJ 08628 (US). **AUGERI, David, J.** [US/US]; 107 Carter Road, Princeton, NJ 08540 (US). **MAGNIN, David, R.** [US/US]; 40 Cottage Court, Hamilton, NJ 08690 (US). **HAMANN, Lawrence, G.** [US/US]; 24 East Riding Drive, Cherry Hill, NJ 08003 (US). **BETEBENNER,****BEST AVAILABLE COPY****WO 01/68603 A2**

(54) Title: CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND METHOD



(57) Abstract: Dipeptidyl peptidase IV (DP 4) inhibiting compounds are provided having the formula (I) where x is 0 or 1 and y is 0 or 1 (provided that x = 1 when y = 0 and x = 0 when y = 1); n is 0 or 1; X is H or CN; and wherein R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, and other diseases as set out herein, employing such DP 4 inhibitor or a combination of such DP 4 inhibitor and one or more of another antidiabetic agent such as metformin, glyburide, troglitazone, pioglitazone, rosiglitazone and/or insulin and/or one or more of a hypolipidemic agent and/or anti-obesity agent and/or other therapeutic agent.

CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF
DIPEPTIDYL PEPTIDASE IV AND METHOD

5 The present invention relates to cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV (DP-4), and to a method for treating diabetes, especially Type II diabetes, as well as hyperglycemia, Syndrome X, diabetic complications, hyperinsulinemia, obesity,
10 atherosclerosis and related diseases, as well as various immunomodulatory diseases and chronic inflammatory bowel disease, employing such cyclopropyl-fused pyrrolidines alone or in combination with another type antidiabetic agent and/or other type therapeutic agent.

15

Depeptidyl peptidase IV (DP-4) is a membrane bound non-classical serine aminopeptidase which is located in a variety of tissues (intestine, liver, lung, kidney) as well as on circulating T-lymphocytes (where the enzyme is known as CD-26). It is responsible for the metabolic cleavage of certain endogenous peptides (GLP-1(7-36), glucagon) in vivo and has demonstrated proteolytic activity against a variety of other peptides (GHRH, NPY, GLP-2, VIP) in vitro.

25


GLP-1(7-36) is a 29 amino-acid peptide derived by post-translational processing of proglucagon in the small intestine. GLP-1(7-36) has multiple actions in vivo including the stimulation of insulin secretion, inhibition of glucagon secretion, the promotion of satiety, and the slowing of gastric emptying. Based on its physiological profile, the actions of GLP-1(7-36) are expected to be beneficial in the prevention and treatment of type II diabetes and potentially obesity. To support

this claim, exogenous administration of GLP-1(7-36) (continuous infusion) in diabetic patients has demonstrated efficacy in this patient population. Unfortunately GLP-1(7-36) is degraded rapidly in vivo and 5 has been shown to have a short half-life in vivo ($t_{1/2} \approx 1.5$ min). Based on a study of genetically bred DP-4 KO mice and on in vivo/in vitro studies with selective DP-4 inhibitors, DP-4 has been shown to be the primary degrading enzyme of GLP-1(7-36) in vivo. GLP-1(7-36) is 10 degraded by DP-4 efficiently to GLP-1(9-36), which has been speculated to act as a physiological antagonist to GLP-1(7-36). Thus, inhibition of DP-4 in vivo should potentiate endogenous levels of GLP-1(7-36) and attenuate formation of its antagonist GLP-1(9-36) and thus serve to 15 ameliorate the diabetic condition.

In accordance with the present invention, cyclopropyl-fused pyrrolidine-based compounds are provided which inhibit DP-4 and have the structure

20

I



wherein x is 0 or 1 and y is 0 or 1 (provided that
 $x = 1$ when $y = 0$ and
 $x = 0$ when $y = 1$);
25 n is 0 or 1;
 X is H or CN (that is cyano);
 R¹, R², R³ and R⁴ are the same or different and are independently selected from H, alkyl, alkenyl, alkynyl,
30 cycloalkyl, cycloalkylalkyl, bicycloalkyl, tricycloalkyl, alkylcycloalkyl, hydroxyalkyl, hydroxyalkylcycloalkyl, hydroxycycloalkyl, hydroxybicycloalkyl, hydroxytricycloalkyl, bicycloalkylalkyl, alkylthioalkyl,

arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl and cycloheteroalkylalkyl, all optionally substituted through available carbon atoms with 1, 2, 3, 4 or 5 groups

5 selected from hydrogen, halo, alkyl, polyhaloalkyl, alkoxy, haloalkoxy, polyhaloalkoxy, alkoxycarbonyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, heteroaryl amino, aryl amino, cycloheteroalkyl, cycloheteroalkylalkyl, hydroxy,

10 hydroxyalkyl, nitro, cyano, amino, substituted amino, alkylamino, dialkylamino, thiol, alkylthio, alkylcarbonyl, acyl, alkoxycarbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyloxy,

15 alkylcarbonylamino, arylcarbonylamino, alkylsulfonylamino, alkylaminocarbonylamino, alkoxycarbonylamino, alkylsulfonyl, aminosulfonyl, alkylsulfinyl, sulfonamido or sulfonyl;

and R¹ and R³ may optionally be taken together to


20 form -(CR⁵R⁶)_m- where m is 2 to 6, and R⁵ and R⁶ are the same or different and are independently selected from hydroxy, alkoxy, cyano, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,

25 halo, amino, substituted amino, cycloheteroalkylalkyl, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino, alkoxycarbonyl, aryloxycarbonyl, or alkylaminocarbonylamino, or R¹ and R⁴ may optionally be


30 taken together to form -(CR⁷R⁸)_p- where p is 2 to 6, and R⁷ and R⁸ are the same or different and are independently selected from hydroxy, alkoxy, cyano, H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl,

35 halo, amino, substituted amino, cycloheteroalkylalkyl, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino,

alkoxycarbonyl, aryloxycarbonyl, or alkylaminocarbonylamino, or optionally R¹ and R³ together



with R⁴ form a 5 to 7 membered ring containing a total of 2 to 4 heteroatoms selected from N, O, S, SO, or 5 SO₂;




or optionally R¹ and R³ together with R⁴ form a 4 to 8 membered cycloheteroalkyl ring wherein the cycloheteroalkyl ring has an optional aryl ring fused thereto or an optional 3 to 7 membered cycloalkyl ring fused thereto;


and including pharmaceutically acceptable salts thereof, and prodrug esters thereof, and all stereoisomers thereof.

Thus, the compounds of formula I of the invention 15 include the following structures

IA



IB



20

In addition, in accordance with the present invention, a method is provided for treating diabetes, especially Type II diabetes, as well as impaired glucose homeostasis, impaired glucose tolerance, infertility, 25 polycystic ovary syndrome, growth disorders, frailty, arthritis, allograft rejection in transplantation, autoimmune diseases (such as scleroderma and

multiple sclerosis), various immunomodulatory diseases (such as lupus erythematosis or psoriasis), AIDS, intestinal diseases (such as necrotizing enteritis, microvillus inclusion disease or celiac disease),
5 inflammatory bowel syndrome, chemotherapy-induced intestinal mucosal atrophy or injury, anorexia nervosa, osteoporosis, Syndrome X, dysmetabolic syndrome, diabetic complications, hyperinsulinemia, obesity, atherosclerosis and related diseases, as well as inflammatory bowel
10 disease (such as Crohn's disease and ulcerative colitis), wherein a therapeutically effective amount of a compound of structure I (which inhibits DP 4) is administered to a human patient in need of treatment.

The conditions, diseases, and maladies collectively
15 referenced to as "Syndrome X" or Metabolic Syndrome are detailed in Johannsson *J. Clin. Endocrinol. Metab.*, 82, 727-734 (1997).

In addition, in accordance with the present invention, a method is provided for treating diabetes and
20 related diseases as defined above and hereinafter as well as any of the other disease states mentioned above, wherein a therapeutically effective amount of a combination of a compound of structure I and one, two, three or more of other types of antidiabetic agent(s)
25 (which may be employed to treat diabetes and related diseases) and/or one, two or three or more other types of therapeutic agent(s) is administered to a human patient in need of treatment.

The term "diabetes and related diseases" refers to
30 Type II diabetes, Type I diabetes, impaired glucose tolerance, obesity, hyperglycemia, Syndrome X, dysmetabolic syndrome, diabetic complications, dysmetabolic syndrome, and hyperinsulinemia.

The conditions, diseases and maladies collectively
35 referred to as "diabetic complications" include retinopathy, neuropathy and nephropathy, and other known complications of diabetes.

The term "other type(s) of therapeutic agents" as employed herein refers to one or more antidiabetic agents (other than DP4 inhibitors of formula I), one or more anti-obesity agents, and/or one or more lipid-modulating agents (including anti-atherosclerosis agents), and/or one or more infertility agents, one or more agents for treating polycystic ovary syndrome, one or more agents for treating growth disorders, one or more agents for treating frailty, one or more agents for treating arthritis, one or more agents for preventing allograft rejection in transplantation, one or more agents for treating autoimmune diseases, one or more anti-AIDS agents, one or more anti-osteoporosis agents, one or more agents for treating immunomodulatory diseases, one or more agents for treating chronic inflammatory bowel disease or syndrome and/or one or more agents for treating anorexia nervosa.

The term "lipid-modulating" agent as employed herein refers to agents which lower LDL and/or raise HDL and/or lower triglycerides and/or lower total cholesterol and/or other known mechanisms for therapeutically treating lipid disorders.

In the above methods of the invention, the compound of structure I will be employed in a weight ratio to the antidiabetic agent or other type therapeutic agent (depending upon its mode of operation) within the range from about 0.01:1 to about 500:1, preferably from about 0.1:1 to about 100:1, more preferably from about 0.2:1 to about 10:1.

Preferred are compounds of formula I wherein R³ is H or alkyl, R¹ is H, alkyl, cycloalkyl, bicycloalkyl, tricycloalkyl, alkylcycloalkyl, hydroxyalkyl, hydroxytricycloalkyl, hydroxycycloalkyl, hydroxybicycloalkyl, or hydroxyalkylcycloalkyl, R² is H or alkyl, n is 0, X is CN, x is 0 or 1 and y is 0 or 1.



Most preferred are preferred compounds of formula

I as described above where X is CN or $\text{---}\text{CN}$,

and/or wherein the fused cyclopropyl group is


identified as .

- 5 Thus, preferred compounds of formula I of the invention will include the moiety:




10

or




Particularly preferred are the following compounds:

15




[1S,2(2S),3S,5S]

- wherein R¹ is alkyl, cycloalkyl, bicycloalkyl,
tricycloalkyl, alkylcycloalkyl, hydroxyalkyl,
20 hydroxycycloalkyl, hydroxyalkylcycloalkyl,
hydroxybicycloalkyl or hydroxytricycloalkyl;



[1R,2S,3(2S),5S]

- wherein R¹ is alkyl, cycloalkyl, bicycloalkyl,
tricycloalkyl, hydroxybicycloalkyl, hydroxytricycloalkyl,
5 alkylcycloalkyl, hydroxyalkyl, hydroxycycloalkyl or
hydroxyalkylcycloalkyl as well as the following:



- 15 Compounds of the structure I may be generated by the methods as shown in the following reaction schemes and the description thereof.

Referring to Reaction Scheme 1, compound 1, where PG₁ is a common amine protecting group such as Boc, Cbz, 20 or FMOC and X¹ is H or CO₂R⁹ as set out below, may be generated by methods as described herein or in the literature (for example see Sagnard et al, Tet-Lett., 1995, 36, pp. 3148-3152, Tverezovsky et al, Tetrahedron,

1997, 53, pp. 14773-14792, Hanessian et al, Bioorg. Med. Chem. Lett., 1998, 8, p. 2123-2128). Removal of the PG₁ group by conventional methods (e.g. (1) TFA or HCl when PG₁ is Boc, or (2) H₂/Pd/C, TMSI when PG₁ is Cbz, or (3) Et₂NH when PG₁ is (FMOC) affords the free amine 2. Amine 2 may be coupled to various protected amino acids such as 3 (where PG₂ can be any of the PG₁ protecting groups) using standard peptide coupling conditions (e.g. EDAC/HOAT, i-BuOCOC₁/TEA, PyBop/NMM) to afford the corresponding dipeptide 4. Removal of the amine protecting group PG₂ provides compound Ia of the invention where X=H.


In the case where X¹=CO₂R⁹ (where R⁹ is alkyl or aralkyl groups such as methyl, ethyl, t-butyl, or benzyl), the ester may be hydrolyzed under a variety of conditions, for example with aqueous NaOH in a suitable solvent such as methanol, THF, or dioxane, to provide the acid 5. Conversion of the acid group to the primary carboxamide, affording 6, may be effected by activation of the acid group (e.g. employing i-BuOCOC₁/TEA or EDAC) followed by treatment with NH₃ or an ammonia equivalent in a solvent such as dioxane, ether, or methanol. The amide functionality may be converted to the nitrile group by a variety of standard conditions (e.g. POCl₃/pyridine/imidazole or cyanuric chloride/DMF or trifluoroacetic anhydride, THF, pyridine) to give 7. Finally, removal of the PG₂ protecting group similar to above provides compound of the invention Ib.

In a different sequence (Scheme 2), compound 1 where X¹ is CO₂R⁹ may be saponified to the acid and subsequently amidated as described above to give amide 8. Removal of the PG₁ group followed by peptide coupling to 3 affords compound 6, an intermediate in the synthesis of Ib.

Alternately, the carboxamide group in 8 may be converted to the nitrile as described above to give compound 9. Deprotection of PG₁ affords 10 which may be


subject to standard peptide coupling conditions to afford 7, an intermediate in the synthesis of Ib. Compound 10 may also be generated by oxidation of the amine 2 (e.g. NCS) followed by hydrolysis and subsequent cyanide treatment. Compound 10 may be obtained as a mixture of stereoisomers or a single isomer/diastereomer which may be epimerized (employing conventional procedures) to afford a mixture of stereoisomers.

10 Scheme 1




a. $\text{PG}_1 = \text{Boc}$, TFA or HCl; $\text{PG}_1 = \text{Cbz}$, $\text{H}_2/\text{Pd/C}$ or TMSI; $\text{PG}_1 = \text{FMOC}$, Et_2NH b. EDAC, HOBT, DMF or $i\text{-BuOCOCl}/\text{TEA}$ or PyBop, NMM c. $\text{PG}_2 = \text{PG}_1$, (see conditions for a) d. LiOH or NaOH MeOH or THF/H₂O or dioxane e. $i\text{-BuOCOCl}/\text{NMM}$ or $i\text{-BuOCOCl}/\text{TEA}$ or EDAC, then NH_3 in dioxane or Et_2O f. POCl_3 , pyridine, imidazole or cyanuric chloride, DMF or TFAA, THF, pyridine.

Scheme 2



a. LiOH or NaOH in MeOH or THF/H₂O or dioxane b. i-BuOCOCl/ NMM or i-BuOCOCl/TEA or EDAC, then NH₃ in dioxane or Et₂O c. PG₁ =Boc, TFA or HCl; PG₁ = Cbz, H₂/Pd/C or TMSI; PG₁ = FMOC, Et₂NH d. EDAC, HOBT, DMF or i-BuOCOCl/ TEA or PyBop, NMM e. POCl₃, pyridine, imidazole or cyanuric chloride, DMF.

5 In a like manner, β -amino acids such as




may be coupled with 2, the free amine of 8, or 10 to give the corresponding amides which may be converted to the β -amino acid derivatives of compound Ia or Ib following the same chemistry.

Unless otherwise indicated, the term "lower alkyl", "alkyl" or "alk" as employed herein alone or as part of another group includes both straight and branched chain hydrocarbons, containing 1 to 20 carbons, preferably 1 to 10 carbons, more preferably 1 to 8 carbons, in the normal chain, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethyl-pentyl, nonyl, decyl, undecyl, dodecyl,

the various branched chain isomers thereof, and the like as well as such groups including 1 to 4 substituents such as halo, for example F, Br, Cl or I or CF₃, alkyl, alkoxy, aryl, aryloxy, aryl(aryl) or diaryl, arylalkyl,
 5 arylalkyloxy, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkyloxy, amino, hydroxy, hydroxyalkyl, acyl, heteroaryl, heteroaryloxy, heteroarylalkyl, heteroarylalkoxy, aryloxyalkyl, alkylthio, arylalkylthio, aryloxyaryl, alkylamido, alkanoylamino,
 10 arylcarbonylamino, nitro, cyano, thiol, haloalkyl, trihaloalkyl and/or alkylthio.


Unless otherwise indicated, the term "cycloalkyl" as employed herein alone or as part of another group includes saturated or partially unsaturated (containing 1
 15 or 2 double bonds) cyclic hydrocarbon groups containing 1 to 3 rings, including monocyclic alkyl, bicyclic alkyl (or bicycloalkyl) and tricyclic alkyl (tricycloalkyl), containing a total of 3 to 20 carbons forming the ring, preferably 3 to 10 carbons, forming the ring and which
 20 may be fused to 1 or 2 aromatic rings as described for aryl, which includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl, cyclohexenyl, adamantyl,



any of which groups may be optionally substituted with 1 to 4 substituents such as halogen, alkyl, alkoxy,
 30 hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, hydroxyalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol and/or alkylthio and/or any of the substituents for alkyl.

The term "cycloalkenyl" as employed herein alone or as part of another group refers to cyclic hydrocarbons containing 3 to 12 carbons, preferably 5 to 10 carbons and 1 or 2 double bonds. Exemplary cycloalkenyl groups 5 include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclohexadienyl, and cycloheptadienyl, which may be optionally substituted as defined for cycloalkyl.

The term "cycloalkylene" as employed herein refers 10 to a "cycloalkyl" group which includes free bonds and thus is a linking group such as



and the like, and may optionally be substituted as defined above for "cycloalkyl".

The term "alkanoyl" as used herein alone or as 15 part of another group refers to alkyl linked to a carbonyl group.

Unless otherwise indicated, the term "lower alkenyl" or "alkenyl" as used herein by itself or as part of another group refers to straight or branched chain 20 radicals of 2 to 20 carbons, preferably 2 to 12 carbons, and more preferably 1 to 8 carbons in the normal chain, which include one to six double bonds in the normal chain, such as vinyl, 2-propenyl, 3-butenyl, 2-butenyl, 4-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl, 2-heptenyl, 25 3-heptenyl, 4-heptenyl, 3-octenyl, 3-nonenyl, 4-decenyl, 3-undecenyl, 4-dodecenyl, 4,8,12-tetradecatrienyl, and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, 30 amino, hydroxy, heteroaryl, cycloheteroalkyl, alkanoylamino, alkylamido, arylcarbonyl-amino, nitro, cyano, thiol, alkylthio and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower alkynyl" or "alkynyl" as used herein by itself or as part of another group refers to straight or branched chain

radicals of 2 to 20 carbons, preferably 2 to 12 carbons and more preferably 2 to 8 carbons in the normal chain, which include one triple bond in the normal chain, such as 2-propynyl, 3-butynyl, 2-butynyl, 4-pentynyl, 3-
5 pentynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, 4-decynyl, 3-undecynyl, 4-dodecynyl and the like, and which may be optionally substituted with 1 to 4 substituents, namely, halogen, haloalkyl, alkyl, alkoxy, alkenyl, alkynyl, aryl,
10 arylalkyl, cycloalkyl, amino, heteroaryl, cycloheteroalkyl, hydroxy, alkanoylamino, alkylamido, arylcarbonylamino, nitro, cyano, thiol, and/or alkylthio, and/or any of the alkyl substituents set out herein.

The terms "arylalkenyl" and "arylalkynyl" as used
15 alone or as part of another group refer to alkenyl and alkynyl groups as described above having an aryl substituent.

Where alkyl groups as defined above have single bonds for attachment to other groups at two different carbon atoms, they are termed "alkylene" groups and may
20 optionally be substituted as defined above for "alkyl".


Where alkenyl groups as defined above and alkynyl groups as defined above, respectively, have single bonds for attachment at two different carbon atoms, they are termed "alkenylene groups" and "alkynylene groups", respectively, and may optionally be substituted as defined above for "alkenyl" and "alkynyl".

The term "halogen" or "halo" as used herein alone
30 or as part of another group refers to chlorine, bromine, fluorine, and iodine as well as CF₃, with chlorine or fluorine being preferred.

The term "metal ion" refers to alkali metal ions such as sodium, potassium or lithium and alkaline earth
35 metal ions such as magnesium and calcium, as well as zinc and aluminum.

Unless otherwise indicated, the term "aryl" as employed herein alone or as part of another group refers to monocyclic and bicyclic aromatic groups containing 6 to 10 carbons in the ring portion (such as phenyl or naphthyl including 1-naphthyl and 2-naphthyl) and may optionally include one to three additional rings fused to a carbocyclic ring or a heterocyclic ring (such as aryl, cycloalkyl, heteroaryl or cycloheteroalkyl rings for example

10



and may be optionally substituted through available carbon atoms with 1, 2, or 3 groups selected from hydrogen, halo, haloalkyl, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylthio, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylhetereoaryl, heteroaryloxy, hydroxy, nitro, cyano, amino, substituted amino wherein the amino includes 1 or 2 substituents (which are alkyl, aryl or any of the other aryl compounds mentioned in the definitions), thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl,

arylsulfonylamino or arylsulfon-aminocarbonyl and/or any of the alkyl substituents set out herein.

Unless otherwise indicated, the term "lower alkoxy", "alkoxy", "aryloxy" or "aralkoxy" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to an oxygen atom.

Unless otherwise indicated, the term "substituted amino" as employed herein alone or as part of another group refers to amino substituted with one or two substituents, which may be the same or different, such as alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or thioalkyl. These substituents may be further substituted with any of the R¹ groups or substituents for R¹ as set out above. In addition, the amino substituents may be taken together with the nitrogen atom to which they are attached to form 1-pyrrolidinyl, 1-piperidinyl, 1-azepinyl, 4-morpholinyl, 4-thiamorpholinyl, 1-piperazinyl, 4-alkyl-1-piperazinyl, 4-arylalkyl-1-piperazinyl, 4-diarylalkyl-1-piperazinyl, 1-pyrrolidinyl, 1-piperidinyl, or 1-azepinyl, optionally substituted with alkyl, alkoxy, alkylthio, halo, trifluoromethyl or hydroxy.

Unless otherwise indicated, the term "lower alkylthio", alkylthio", "arylthio" or "aralkylthio" as employed herein alone or as part of another group includes any of the above alkyl, aralkyl or aryl groups linked to a sulfur atom.


Unless otherwise indicated, the term "lower alkylamino", "alkylamino", "arylamino", or "arylalkylamino" as employed herein alone or as part of another group includes any of the above alkyl, aryl or arylalkyl groups linked to a nitrogen atom.

Unless otherwise indicated, the term "acyl" as employed herein by itself or part of another group, as

defined herein, refers to an organic radical linked to a carbonyl ($\text{C}=\text{O}$) group; examples of acyl groups include any of the R¹ groups attached to a carbonyl, such as alkanoyl, alkenoyl, aroyl, aralkanoyl, heteroaroyl, 5 cycloalkanoyl, cycloheteroalkanoyl and the like.

Unless otherwise indicated, the term "cycloheteroalkyl" as used herein alone or as part of another group refers to a 5-, 6- or 7-membered saturated or partially unsaturated ring which includes 1 to 2 10 hetero atoms such as nitrogen, oxygen and/or sulfur, linked through a carbon atom or a heteroatom, where possible, optionally via the linker (CH₂)_r (where r is 1, 2 or 3), such as:


15




and the like. The above groups may include 1 to 4 20 substituents such as alkyl, halo, oxo and/or any of the alkyl substituents set out herein. In addition, any of the cycloheteroalkyl rings can be fused to a cycloalkyl, aryl, heteroaryl or cycloheteroalkyl ring.

Unless otherwise indicated, the term "heteroaryl" 25 as used herein alone or as part of another group refers to a 5- or 6- membered aromatic ring which includes 1, 2,

3 or 4 hetero atoms such as nitrogen, oxygen or sulfur, and such rings fused to an aryl, cycloalkyl, heteroaryl or cycloheteroalkyl ring (e.g. benzothiophenyl, indolyl), and includes possible N-oxides. The heteroaryl group may 5 optionally include 1 to 4 substituents such as any of the substituents set out above for alkyl. Examples of heteroaryl groups include the following:



10



15 and the like.

The term "cycloheteroalkylalkyl" as used herein alone or as part of another group refers to cycloheteroalkyl groups as defined above linked through a C atom or heteroatom to a $(CH_2)_r$ chain.

20 The term "heteroarylalkyl" or "heteroarylalkenyl" as used herein alone or as part of another group refers to a heteroaryl group as defined above linked through a C atom or heteroatom to a $-(CH_2)_r-$ chain, alkylene or alkenylene as defined above.

25 The term "polyhaloalkyl" as used herein refers to an "alkyl" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as CF_3CH_2 , CF_3 or $CF_3CF_2CH_2$.

The term "polyhaloalkoxy" as used herein refers to an "alkoxy" or "alkyloxy" group as defined above which includes from 2 to 9, preferably from 2 to 5, halo substituents, such as F or Cl, preferably F, such as
5 CF₃CH₂O, CF₃O or CF₃CF₂CH₂O.

All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form. The compounds of the present invention can have asymmetric centers at any of
10 the carbon atoms including any one or the R substituents. Consequently, compounds of formula I can exist in enantiomeric or diastereomeric forms or in mixtures thereof. The processes for preparation can utilize
15 racemates, enantiomers or diastereomers as starting materials. When diastereomeric or enantiomeric products are prepared, they can be separated by conventional methods for example, chromatographic or fractional crystallization.

Where desired, the compounds of structure I may be
20 used in combination with one or more other types of antidiabetic agents (employed to treat diabetes and related diseases) and/or one or more other types of therapeutic agents which may be administered orally in the same dosage form, in a separate oral dosage form or
25 by injection.

The other type of antidiabetic agent which may be optionally employed in combination with the DP4 inhibitor of formula I may be 1, 2, 3 or more antidiabetic agents or antihyperglycemic agents including insulin secretagogues
30 or insulin sensitizers, or other antidiabetic agents preferably having a mechanism of action different from DP4 inhibition and may include biguanides, sulfonyl ureas, glucosidase inhibitors, PPAR γ agonists, such as thiazolidinediones, SGLT2 inhibitors, PPAR α/γ dual
35 agonists, aP2 inhibitors, glycogen phosphorylase inhibitors, advanced glycosylation end (AGE) products inhibitors, and/or meglitinides, as well as insulin,

and/or glucagon-like peptide-1 (GLP-1) or mimetics thereof.

It is believed that the use of the compounds of structure I in combination with 1, 2, 3 or more other 5 antidiabetic agents produces antihyperglycemic results greater than that possible from each of these medicaments alone and greater than the combined additive anti-hyperglycemic effects produced by these medicaments.

The other antidiabetic agent may be an oral 10 antihyperglycemic agent preferably a biguanide such as metformin or phenformin or salts thereof, preferably metformin HCl.

Where the other antidiabetic agent is a biguanide, the compounds of structure I will be employed in a weight 15 ratio to biguanide within the range from about 0.01:1 to about 100:1, preferably from about 0.1:1 to about 5:1.

The other antidiabetic agent may also preferably be a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 20 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the β -cells, with glyburide and glipizide being preferred, which may be administered in the same or in separate oral 25 dosage forms.

The compounds of structure I will be employed in a weight ratio to the sulfonyl urea in the range from about 0.01:1 to about 100:1, preferably from about 0.05:1 to about 5:1.

30 The oral antidiabetic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436), which may be administered in the same or in a separate oral dosage forms.

35 The compounds of structure I will be employed in a weight ratio to the glucosidase inhibitor within the

range from about 0.01:1 to about 100:1, preferably from about 0.2:1 to about 50:1.

- The compounds of structure I may be employed in combination with a PPAR γ agonist such as a
- 5 thiazolidinedione oral anti-diabetic agent or other insulin sensitizers (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin $^{\circ}$, disclosed in U.S. Patent No. 4,572,912), rosiglitazone (SKB), pioglitazone (Takeda),
- 10 Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016), Glaxo-Wellcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer, isaglitazone (MIT/J&J), JTT-501 (JPNT/P&U), L-895645 (Merck), R-119702 (Sankyo/WL), NN-2344 (Dr. Reddy/NN), or
- 15 YM-440 (Yamanouchi), preferably rosiglitazone and pioglitazone.

The compounds of structure I will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 0.01:1 to about 100:1, preferably

20 from about 0.1:1 to about 10:1.

- The sulfonyl urea and thiazolidinedione in amounts of less than about 150 mg oral antidiabetic agent may be incorporated in a single tablet with the compounds of structure I.
- 25 The compounds of structure I may also be employed in combination with a antihyperglycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener,
- 30 disclosure of which is incorporated herein by reference), or a GLP-1 mimic such as AC2993 or Exendin-4 (Amylin) and LY-315902 or LY-307167 (Lilly) and NN2211 (Novo-Nordisk), which may be administered via injection, intranasal, or by transdermal or buccal devices.
- 35 Where present, metformin, the sulfonyl ureas, such as glyburide, glimepiride, glipyride, glipizide, chlorpropamide and gliclazide and the glucosidase

inhibitors acarbose or miglitol or insulin (injectable, pulmonary, buccal, or oral) may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference (PDR).

5 Where present, metformin or salt thereof may be employed in amounts within the range from about 500 to about 2000 mg per day which may be administered in single or divided doses one to four times daily.

10 Where present, the thiazolidinedione anti-diabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

15 Where present insulin may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

Where present GLP-1 peptides may be administered in oral buccal formulations, by nasal administration (for example inhalation spray) or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 20 5,631,224 which are incorporated herein by reference.

The other antidiabetic agent may also be a PPAR α/γ dual agonist such as AR-HO39242 (Astra/Zeneca), GW-409544 (Glaxo-Wellcome), KRP297 (Kyorin Merck) as well as those disclosed by Murakami et al, "A Novel Insulin Sensitizer 25 Acts As a Coligand for Peroxisome Proliferation - Activated Receptor Alpha (PPAR alpha) and PPAR gamma. Effect on PPAR alpha Activation on Abnormal Lipid Metabolism in Liver of Zucker Fatty Rats", Diabetes 47, 1841-1847 (1998), and in U.S. application Serial No. 30 09/664,598, filed September 18, 2000, (attorney file LA29NP) the disclosure of which is incorporated herein by reference, employing dosages as set out therein, which compounds designated as preferred are preferred for use herein.

35 The other antidiabetic agent may be an SGLT2 inhibitor such as disclosed in U.S. application Serial No. 09/679,027, filed October 4, 2000 (attorney file

LA49NP), which is incorporated herein by reference, employing dosages as set out herein. Preferred are the compounds designated as preferred in the above application.

5 The other antidiabetic agent which may be optionally employed in combination with the DP4 inhibitor of formula I may be an aP2 inhibitor such as disclosed in U.S. application Serial No. 09/391,053, filed September 7, 1999, and U.S. application Serial No. 09/519,079, 10 filed March 6, 2000 (attorney file LA27NP), which is incorporated herein by reference, employing dosages as set out herein. Preferred are the compounds designated as preferred in the above application.

10 The other antidiabetic agent which may be 15 optionally employed in combination with the DP4 inhibitor of formula I may be a glycogen phosphorylase inhibitor such as disclosed in WO 96/39384, WO 96/39385, EP 978279, WO 2000/47206, WO 99/43663, and U.S. Patent Nos. 5,952,322 and 5,998,463, WO 99/26659 and EP 1041068.

20 The meglitinide which may optionally be employed in combination with the compound of formula I of the invention may be repaglinide, nateglinide (Novartis) or KAD1229 (PF/Kissei), with repaglinide being preferred.

25 The DP4 inhibitor of formula I will be employed in a weight ratio to the meglitinide, PPAR γ agonist, PPAR α/γ dual agonist, SGLT2 inhibitor, aP2 inhibitor, or glycogen phosphorylase inhibitor within the range from about 0.01:1 to about 100:1, preferably from about 0.1:1 to about 10:1.


30 The hypolipidemic agent or lipid-modulating agent which may be optionally employed in combination with the compounds of formula I of the invention may include 1,2,3 or more MTP inhibitors, HMG CoA reductase inhibitors, squalene synthetase inhibitors, fibrin acid derivatives, 35 ACAT inhibitors, lipoxygenase inhibitors, cholesterol absorption inhibitors, ileal Na⁺/bile acid cotransporter inhibitors, upregulators of LDL receptor activity, ATP

citrate lyase inhibitors, cholesteryl ester transfer protein inhibitors, bile acid sequestrants, and/or nicotinic acid and derivatives thereof.

- MTP inhibitors employed herein include MTP
- 5 inhibitors disclosed in U.S. Patent No. 5,595,872, U.S. Patent No. 5,739,135, U.S. Patent No. 5,712,279, U.S. Patent No. 5,760,246, U.S. Patent No. 5,827,875, U.S. Patent No. 5,885,983 and U.S. Application Serial No. 09/175,180 filed October 20, 1998, now U.S. Patent No.
- 10 15,962,440. Preferred are each of the preferred MTP inhibitors disclosed in each of the above patents and applications.

All of the above U.S. Patents and applications are incorporated herein by reference.

- 15 Most preferred MTP inhibitors to be employed in accordance with the present invention include preferred MTP inhibitors as set out in U.S. Patent Nos. 5,739,135 and 5,712,279, and U.S. Patent No. 5,760,246 as well as implitapide (Bayer).
- 20 The most preferred MTP inhibitor is 9-[4-[4-[[2-(2,2,2-Trifluoroethoxy)benzoyl]amino]-1-piperidinyl]butyl]-N-(2,2,2-trifluoroethyl)-9H-fluorene-9-carboxamide



- 25 The hypolipidemic agent may be an HMG CoA reductase inhibitor which includes, but is not limited to, mevastatin and related compounds as disclosed in U.S. Patent No. 3,983,140, lovastatin (mevinolin) and related compounds as disclosed in U.S. Patent No. 4,231,938,
- 30 pravastatin and related compounds such as disclosed in

U.S. Patent No. 4,346,227, simvastatin and related compounds as disclosed in U.S. Patent Nos. 4,448,784 and 4,450,171. Other HMG CoA reductase inhibitors which may be employed herein include, but are not limited to,
5 fluvastatin, disclosed in U.S. Patent No. 5,354,772, cerivastatin disclosed in U.S. Patent Nos. 5,006,530 and 5,177,080, atorvastatin disclosed in U.S. Patent Nos. 4,681,893, 5,273,995, 5,385,929 and 5,686,104, atavastatin (Nissan/Sankyo's nisvastatin (NK-104))
10 disclosed in U.S. Patent No. 5,011,930, Shionogi-Astra/Zeneca visastatin (ZD-4522) disclosed in U.S. Patent No. 5,260,440.

The squalene synthetase inhibitors suitable for use herein include, but are not limited to, α -phosphono-sulfonates disclosed in U.S. Patent No. 5,712,396, those disclosed by Biller et al, J. Med. Chem., 1988, Vol. 31, No. 10, pp 1869-1871, including isoprenoid (phosphinyl-methyl)phosphonates as well as other known squalene synthetase inhibitors, for example, as disclosed in U.S. Patent No. 4,871,721 and 4,924,024 and in Biller, S.A., Neuenschwander, K., Ponpipom, M.M., and Poulter, C.D., Current Pharmaceutical Design, 2, 1-40 (1996).

In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al, J. Med. Chem., 1977, 20, 243-249, the farnesyl diphosphate analog A and presqualene pyrophosphate (PSQ-PP) analogs as disclosed by Corey and Volante, J. Am. Chem. Soc., 1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R.W. et al, J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med. Chem. U of Utah, Abstract, Table of Contents, pp 16, 17, 40-43, 48-51, Summary.

35 Other hypolipidemic agents suitable for use herein include, but are not limited to, fibric acid derivatives, such as fenofibrate, gemfibrozil, clofibrate,

- bezafibrate, ciprofibrate, clinofibrate and the like, probucol, and related compounds as disclosed in U.S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, 5 colestipol and DEAE-Sephadex (Secholex®, Policexide®), as well as lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402), tetrahydrolipstatin (THL), istigmastanylphosphorylcholine (SPC, Roche), aminocyclodextrin (Tanabe 10 Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (disubstituted urea derivatives), nicotinic acid, acipimox, acifran, neomycin, p-aminosalicylic acid, aspirin, 15 poly(diallylmethylamine) derivatives such as disclosed in U.S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U.S. Patent No. 4,027,009, and other known serum cholesterol lowering agents.
- 20 The other hypolipidemic agent may be an ACAT inhibitor such as disclosed in, Drugs of the Future 24, 9-15 (1999), (Avasimibe); "The ACAT inhibitor, Cl-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters", Nicolosi et al, 25 Atherosclerosis (Shannon, Irel). (1998), 137(1), 77-85; "The pharmacological profile of FCE 27677: a novel ACAT inhibitor with potent hypolipidemic activity mediated by selective suppression of the hepatic secretion of ApoB100-containing lipoprotein", Ghiselli, Giancarlo, 30 Cardiovasc. Drug Rev. (1998), 16(1), 16-30; "RP 73163: a bioavailable alkylsulfinyl-diphenylimidazole ACAT inhibitor", Smith, C., et al, Bioorg. Med. Chem. Lett. (1996), 6(1), 47-50; "ACAT inhibitors: physiologic mechanisms for hypolipidemic and anti-atherosclerotic 35 activities in experimental animals", Krause et al, Editor(s): Ruffolo, Robert R., Jr.; Hollinger, Mannfred A., Inflammation: Mediators Pathways (1995), 173-98,

Publisher: CRC, Boca Raton, Fla.; "ACAT inhibitors: potential anti-atherosclerotic agents", Sliskovic et al, Curr. Med. Chem. (1994), 1(3), 204-25; "Inhibitors of acyl-CoA:cholesterol O-acyl transferase (ACAT) as 5 hypocholesterolemic agents. 6. The first water-soluble ACAT inhibitor with lipid-regulating activity. Inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). 7. Development of a series of substituted N-phenyl-N'-(1-phenylcyclopentyl)methyl]ureas with 10 enhanced hypocholesterolemic activity", Stout et al, Chemtracts: Org. Chem. (1995), 8(6), 359-62, or TS-962 (Taisho Pharmaceutical Co. Ltd).

The hypolipidemic agent may be an upregulator of LD2 receptor activity such as MD-700 (Taisho 15 Pharmaceutical Co. Ltd) and LY295427 (Eli Lilly).

The hypolipidemic agent may be a cholesterol absorption inhibitor preferably Schering-Plough's SCH48461 as well as those disclosed in Atherosclerosis 115, 45-63 (1995) and J. Med. Chem. 41, 973 (1998).

20 The hypolipidemic agent may be an ileal Na⁺/bile acid cotransporter inhibitor such as disclosed in Drugs of the Future, 24, 425-430 (1999).

The lipid-modulating agent may be a cholesteryl ester transfer protein (CETP) inhibitor such as Pfizer's 25 CP 529,414 (WO/0038722 and EP 818448) and Pharmacia's SC-744 and SC-795.

The ATP citrate lyase inhibitor which may be employed in the combination of the invention may include, for example, those disclosed in U.S. Patent No. 30 5,447,954.

Preferred hypolipidemic agents are pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin, cerivastatin, atavastatin and ZD-4522.

35 The above-mentioned U.S. patents are incorporated herein by reference. The amounts and dosages employed will be as indicated in the Physician's Desk Reference and/or in the patents set out above.

The compounds of formula I of the invention will be employed in a weight ratio to the hypolipidemic agent (where present), within the range from about 500:1 to about 1:500, preferably from about 100:1 to about 1:100.

5 The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of administration, dosage form and regimen and the desired result.

10 The dosages and formulations for the hypolipidemic agent will be as disclosed in the various patents and applications discussed above.

15 The dosages and formulations for the other hypolipidemic agent to be employed, where applicable, will be as set out in the latest edition of the Physicians' Desk Reference.

For oral administration, a satisfactory result may be obtained employing the MTP inhibitor in an amount within the range of from about 0.01 mg/kg to about 500 mg and preferably from about 0.1 mg 20 to about 100 mg, one to four times daily.

A preferred oral dosage form, such as tablets or capsules, will contain the MTP inhibitor in an amount of from about 1 to about 500 mg, preferably from about 2 to about 400 mg, and more preferably from about 5 to about 25 250 mg, one to four times daily.

For oral administration, a satisfactory result may be obtained employing an HMG CoA reductase inhibitor, for example, pravastatin, lovastatin, simvastatin, atorvastatin, fluvastatin or cerivastatin in dosages 30 employed as indicated in the Physician's Desk Reference, such as in an amount within the range of from about 1 to 2000 mg, and preferably from about 4 to about 200 mg.

The squalene synthetase inhibitor may be employed in dosages in an amount within the range of from about 10 35 mg to about 2000 mg and preferably from about 25 mg to about 200 mg.

A preferred oral dosage form, such as tablets or capsules, will contain the HMG CoA reductase inhibitor in an amount from about 0.1 to about 100 mg, preferably from about 5 to about 80 mg, and more preferably from about 10 to about 40 mg.

A preferred oral dosage form, such as tablets or capsules will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg.

10 The other hypolipidemic agent may also be a lipoxygenase inhibitor including a 15-lipoxygenase (15-LO) inhibitor such as benzimidazole derivatives as disclosed in WO 97/12615, 15-LO inhibitors as disclosed in WO 97/12613, isothiazolones as disclosed in
15 WO 96/38144, and 15-LO inhibitors as disclosed by Sendobry et al "Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties", Brit. J. Pharmacology (1997) 120, 1199-1206, and Cornicelli et al, "15-Lipoxygenase and its
20 Inhibition: A Novel Therapeutic Target for Vascular Disease", Current Pharmaceutical Design, 1999, 5, 11-20.

25 The compounds of formula I and the hypolipidemic agent may be employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.

30 The compositions described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.

35 The preferred hypolipidemic agent is pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin or cerivastatin.

The other type of therapeutic agent which may be optionally employed with the DP4 inhibitor of formula I

may be 1, 2, 3 or more of an anti-obesity agent including a beta 3 adrenergic agonist, a lipase inhibitor, a serotonin (and dopamine) reuptake inhibitor, a thyroid receptor beta drug, an anorectic agent and/or a fatty acid oxidation upregulator.

The beta 3 adrenergic agonist which may be optionally employed in combination with a compound of formula I may be AJ9677 (Takeda/Dainippon), L750355 (Merck), or CP331648 (Pfizer) or other known beta 3 agonists as disclosed in U.S. Patent Nos. 5,541,204, 5,770,615, 5,491,134, 5,776,983 and 5,488,064, with AJ9677, L750,355 and CP331648 being preferred.

The lipase inhibitor which may be optionally employed in combination with a compound of formula I may be orlistat or ATL-962 (Alizyme), with orlistat being preferred.

The serotonin (and dopamine) reuptake inhibitor which may be optionally employed in combination with a compound of formula I may be sibutramine, topiramate (Johnson & Johnson) or axokine (Regeneron), with sibutramine and topiramate being preferred.

The thyroid receptor beta compound which may be optionally employed in combination with a compound of formula I may be a thyroid receptor ligand as disclosed in WO97/21993 (U. Cal SF), WO99/00353 (KaroBio) and GB98/284425 (KaroBio), with compounds of the KaroBio applications being preferred.

The anorectic agent which may be optionally employed in combination with a compound of formula I may be dexamphetamine, phentermine, phenylpropanolamine or mazindol, with dexamphetamine being preferred.

The fatty acid oxidation upregulator which may be optionally employed in combination with the compound of formula I can be famoxin (Genset).

The various anti-obesity agents described above may be employed in the same dosage form with the compound of

formula I or in different dosage forms, in dosages and regimens as generally known in the art or in the PDR.

The infertility agent which may be optionally employed in combination with the DP4 inhibitor of the invention may be 1, 2, or more of clomiphene citrate (Clomid®, Aventis), bromocriptine mesylate (Parlodel®, Novartis), LHRH analogs, Lupron (TAP Pharm.), danazol, Danocrine (Sanofi), progestogens or glucocorticoids, which may be employed in amounts specified in the PDR.

The agent for polycystic ovary syndrome which may be optionally employed in combination with the DP4 inhibitor of the invention may be 1, 2, or more of gonadotropin releasing hormone (GnRH), leuprolide (Lupron®), Clomid®, Parlodel®, oral contraceptives or insulin sensitizers such as PPAR agonists, or other conventional agents for such use which may be employed in amounts specified in the PDR.

The agent for treating growth disorders and/or frailty which may be optionally employed in combination with the DP4 inhibitor of the invention may be 1, 2, or more of a growth hormone or growth hormone secretagogue such as MK-677 (Merck), CP-424,391 (Pfizer), and compounds disclosed in U.S. Serial No. 09/506,749 filed February 18, 2000 (attorney docket LA26), as well as selective androgen receptor modulators (SARMs), which is incorporated herein by reference, which may be employed in amounts specified in the PDR, where applicable.

The agent for treating arthritis which may be optionally employed in combination with the DP4 inhibitor of the invention may be 1, 2, or more of aspirin, indomethacin, ibuprofen, diclofenac sodium, naproxen, nabumetone (Relafen®, SmithKline Beecham), tolmetin sodium (Tolectin®, Ortho-McNeil), piroxicam (Feldene®, Pfizer), ketorolac tromethamine (Toradol®, Roche), celecoxib (Celebrex®, Searle), rofecoxib (Vioxx®, Merck) and the like, which may be employed in amounts specified in the PDR.

Conventional agents for preventing allograft rejection in transplantation such as cyclosporin, Sandimmune (Novartis), azathioprine, Immuran (Faro) or methotrexate may be optionally employed in combination 5 with the DP4 inhibitor of the invention, which may be employed in amounts specified in the PDR.

Conventional agents for treating autoimmune diseases such as multiple sclerosis and immunomodulatory diseases such as lupus erythematosis, psoriasis, for 10 example, azathioprine, Immuran, cyclophosphamide, NSAIDS such as ibuprofen, cox 2 inhibitors such as Vioxx and Celebrex, glucocorticoids and hydroxychloroquine, may be optionally employed in combination with the DP4 inhibitor of the invention, which may be employed in amounts 15 specified in the PDR.

The AIDS agent which may be optionally employed in combination with the DP4 inhibitor of the invention may be a non-nucleoside reverse transcriptase inhibitor, a nucleoside reverse transcriptase inhibitor, a protease 20 inhibitor and/or an AIDS adjunct anti-infective and may be 1, 2, or more of dronabinol (Marinol®, Roxane Labs), didanosine (Videx®, Bristol-Myers Squibb), megestrol acetate (Megace®, Bristol-Myers Squibb), stavudine (Zerit®, Bristol-Myers Squibb), delavirdine mesylate 25 (Rescriptor®, Pharmacia), lamivudine/zidovudine (Combivir™, Glaxo), lamivudine (Epivir™, Glaxo), zalcitabine (Hivid®, Roche), zidovudine (Retrovir®, Glaxo), indinavir sulfate (Crixivan®, Merck), saquinavir (Fortovase™, Roche), saquinavir mesylate (Invirase®, 30 Roche), ritonavir (Norvir®, Abbott), nelfinavir (Viracept®, Agouron).

The above anti-AIDS agents may be employed in amounts specified in the PDR.

The agent for treating inflammatory bowel disease 35 or syndrome which may be optionally employed in combination with the DP4 inhibitor of the invention may be 1, 2, or more of sulfasalazine, salicylates,

mesalamine (Asacol®, P&G) or Zelmac®, (Bristol-Myers Squibb), which may be employed in amounts specified in the PDR or otherwise known in the art.

The agent for treating osteoporosis which may be
5 optionally employed in combination with the DP4 inhibitor
of the invention may be 1, 2, or more of alendronate
sodium (Fosamax®, Merck, tiludronate (Skelid®, Sanofi),
etidronate disodium (Didronel®, P&G), raloxifene HCl
(Evista®, Lilly), which may be employed in amounts
10 specified in the PDR.

In carrying our the method of the invention, a pharmaceutical composition will be employed containing the compounds of structure I, with or without another antidiabetic agent and/or other type therapeutic agent,
15 in association with a pharmaceutical vehicle or diluent. The pharmaceutical composition can be formulated employing conventional solid or liquid vehicles or diluents and pharmaceutical additives of a type appropriate to the mode of desired administration. The
20 compounds can be administered to mammalian species including humans, monkeys, dogs, etc. by an oral route, for example, in the form of tablets, capsules, granules or powders, or they can be administered by a parenteral route in the form of injectable preparations. The dose
25 for adults is preferably between 10 and 1,000 mg per day, which can be administered in a single dose or in the form of individual doses from 1-4 times per day.

A typical capsule for oral administration contains compounds of structure I (250 mg), lactose (75 mg) and
30 magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. 1 gelatin capsule.

A typical injectable preparation is produced by
aseptically placing 250 mg of compounds of structure I
35 into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of

physiological saline, to produce an injectable preparation.

DP4 inhibitor activity of the compounds of the invention may be determined by use of an in vitro assay system which measures the potentiation of inhibition of DP4. Inhibition constants (Ki values) for the DP4 inhibitors of the invention may be determined by the method described below.

10 **Purification of Porcine Dipeptidyl Peptidase IV**

Porcine enzyme was purified as previously described (1), with several modifications. Kidneys from 15-20 animals were obtained, and the cortex was dissected away and frozen at -80°C. Frozen tissue (2000 -2500 g) was homogenized in 12 L of 0.25 M sucrose in a Waring blender. The homogenate then was left at 37°C for 18 hours to facilitate cleavage of DP-4 from cell membranes. After the cleavage step, the homogenate was clarified by centrifugation at 7000 X g for 20 min at 4°C, and the supernatant was collected. Solid ammonium sulfate was added to 60% saturation, and the precipitate was collected by centrifugation at 10,000 X g and was discarded. Additional ammonium sulfate was added to the supernatant to 80% saturation, and the 80% pellet was collected and dissolved in 20 mM Na₂HPO₄, pH 7.4.

After dialysis against 20 mM Na₂HPO₄, pH 7.4, the preparation was clarified by centrifugation at 10,000 X g. The clarified preparation then was applied to 300 mL of ConA Sepharose that had been equilibrated in the same buffer. After washing with buffer to a constant A₂₈₀, the column was eluted with 5% (w/v) methyl α-D-mannopyranoside. Active fractions were pooled, concentrated, and dialyzed against 5 mM sodium acetate, pH 5.0. Dialyzed material then was flowed through a 100 mL Pharmacia Resource S column equilibrated in the same buffer. The flow through material was collected and contained most of the enzyme activity. Active material

again was concentrated and dialyzed into 20 mM Na₂HPO₄, pH 7.4. Lastly, the concentrated enzyme was chromatographed on a Pharmacia S-200 gel filtration column to removed low molecular weight contaminants. Purity of column fractions was analyzed by reducing SDS-PAGE, and the purest fractions were pooled and concentrated. Purified enzyme was stored in 20% glycerol at -80°C.

Assay of Porcine Dipeptidyl Peptidase IV

Enzyme was assayed under steady-state conditions as previously described (2) with gly-pro-p-nitroanilide as substrate, with the following modifications. Reactions contained, in a final volume of 100 µl, 100 mM Aces, 52 mM TRIS, 52 mM ethanolamine, 500 µM gly-pro-p-nitroanilide, 0.2 % DMSO, and 4.5 nM enzyme at 25°C, pH 7.4. For single assays at 10 µM test compound, buffer, compound, and enzyme were added to wells of a 96 well microtiter plate, and were incubated at room temperature for 5 min. Reactions were started by addition of substrate. The continuous production of p-nitroaniline was measured at 405 nm for 15 min using a Molecular Devices Tmax plate reader, with a read every 9 seconds. The linear rate of p-nitroaniline production was obtained over the linear portion of each progress curve. A standard curve for p-nitroaniline absorbance was obtained at the beginning of each experiment, and enzyme catalyzed p-nitroaniline production was quantitated from the standard curve. Compounds giving greater than 50% inhibition were selected for further analysis.

For analysis of positive compounds, steady-state kinetic inhibition constants were determined as a function of both substrate and inhibitor concentration. Substrate saturation curves were obtained at gly-pro-p-nitroanilide concentrations from 60 µM to 3600 µM.

Additional saturation curves also were obtained in the presence of inhibitor. Complete inhibition experiments contained 11 substrate and 7 inhibitor concentrations,

with triplicate determinations across plates. For tight binding inhibitors with K_i s less than 20 nM, the enzyme concentration was reduced to 0.5 nM and reaction times were increased to 120 min. Pooled datasets from the 5 three plates were fitted to the appropriate equation for either competitive, noncompetitive or uncompetitive inhibition.

(1) Rahfeld, J. Schutkowski, M., Faust, J.,
10 Neubert., Barth, A., and Heins, J. (1991) Biol. Chem.
Hoppe-Seyler, 372, 313-318.


(2) Nagatsu, T., Hino, M., Fuyamada, H., Hayakawa,
T., Sakakibara, S., Nakagawa, Y., and Takemoto, T. (1976)
15 Anal. Biochem., 74, 466-476.

The following abbreviations are employed in the Examples and elsewhere herein:

- 20 Ph = phenyl
Bn = benzyl
i-Bu = iso-butyl
Me = methyl
Et = ethyl
25 Pr = propyl
Bu = butyl
TMS = trimethylsilyl
FMOC = fluorenylmethoxycarbonyl
Boc or BOC = *tert*-butoxycarbonyl
30 Cbz = carbobenzyloxy or carbobenzoxy or benzyloxycarbonyl
HOAc or AcOH = acetic acid
DMF = N,N-dimethylformamide
EtOAc = ethyl acetate
THF = tetrahydrofuran
35 TFA = trifluoroacetic acid
Et₂NH = diethylamine
NMM = N-methyl morpholine


- n*-BuLi = *n*-butyllithium
Pd/C = palladium on carbon
PtO₂ = platinum oxide
TEA = triethylamine
- 5 EDAC = 3-ethyl-3'-(dimethylamino)propyl-carbodiimide hydrochloride (or 1-[(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride])
HOBT or HOBT•H₂O = 1-hydroxybenzotriazole hydrate
HOAT = 1-hydroxy-7-azabenzotriazole
- 10 PyBOP reagent = benzotriazol-1-yloxy-tripyrrolidino phosphonium hexafluorophosphate
min = minute(s)
h or hr = hour(s)
L = liter
- 15 mL = milliliter
μL = microliter
g = gram(s)
mg = milligram(s)
mol = mole(s)
- 20 mmol = millimole(s)
meq = milliequivalent
rt = room temperature
sat or sat'd = saturated
aq. = aqueous
- 25 TLC = thin layer chromatography
HPLC = high performance liquid chromatography
LC/MS = high performance liquid chromatography/mass spectrometry
MS or Mass Spec = mass spectrometry
- 30 NMR = nuclear magnetic resonance
mp = melting point

The following Examples represent preferred
35 embodiments of the invention.

Example 1

Step 1.

5



Step 1 title compound was synthesized by following the literature procedure [Stephen Hanessian, Ulrich Reinhold, Michel Saulnier, and Stephen Claridge; Bioorganic & Medicinal Chemistry Letters **8** (1998) 2123-2128] or with the following modifications. L-pyroglutamic acid ethyl ester was N-protected as the t-butylcarbamate (Boc_2O , DMAP or NaH) and then dehydrated to the 4,5-dehydroproline ethyl ester in one pot by carbonyl reduction (triethylborohydride, toluene, -78°C) followed by dehydration (TFAA, lutidine). The title compound was obtained by cyclopropanation of the 4,5-dehydroproline ethyl ester (Et_2Zn , ClCH_2I , 1,2-dichloroethane, -15°C). A more detailed protocol is as follows:


Synthesis of 4,5-dehydro-L-proline ethyl ester: L-pyroglutamic acid ethyl ester (200 g, 1.27 mol) was dissolved in 1.2 liters of methylene chloride and treated sequentially with di-tert-butyldicarbonate (297 g, 1.36 mol) and a catalytic DMAP (1.55 g, 0.013 mol) at ambient temperature. After 6 h, the mixture was quenched with

saturated brine and the organic phase was dried (Na_2SO_4) and filtered through a short silica gel column to give 323 g (100%) of N-Boc- L-pyroglutamic acid ethyl ester.

N-Boc- L-pyroglutamic acid ethyl ester (160 g, 0.62 mol) 5 was dissolved in 1 liter of toluene, cooled to -78°C and treated with lithium triethylborohydride (666 mL of a 1.0 M soln in THF) and added dropwise over 90 minutes. After 3 h, 2,6-lutidine (423 mL, 3.73 mol) was added dropwise followed by DMAP (0.2 g, 0.0016 mol). To this mixture 10 was added TFAA (157 g, 0.74 mol) and the reaction was allowed to come to ambient temperature over 2 h. The mixture was diluted with EtOAc and water and the organics were washed with 3 N HCl, water, aqueous bicarbonate and brine and dried (Na_2SO_4) and filtered through a silica gel 15 plug to give 165 g of the crude 4,5-dehydroproline ethyl ester that was purified by flash column chromatography on silica gel with 1:5 ethyl acetate:hexanes to give 120 g, 75% of the olefin.

20 Cyclopropanation of 4,5-dehydro-L-proline ethyl ester: 4,5-Dehydro-L-proline ethyl ester (35.0 g, 0.145 mol) was added to a solution of neat Et_2Zn (35.8 g, 0.209 mol) in 1 liter of 1,2-dichloroethane at -15°C. To this mixture was added a dropwise addition of ClCH_2I (102 g, 0.58 mol) over 25 1 h and the mixture stirred at -15°C for 18 h. The reaction was quenched with saturated aqueous bicarbonate and the solvent was evaporated and the reaction was taken up in EtOAc, washed with brine and purified by silica gel chromatography using a stepwise gradient of from 20% EtOAc/hexanes to 50% EtOAc/hexanes to give 17.5 g (50%) 30 of diastereomerically pure step 1 title compound.


Step 2.



To a stirred solution of Step 1 compound (411 mg, 1.61 mmol) in CH₂Cl₂ (1.5 mL) at rt was added TFA (1.5 mL).

- 5 The reaction mixture was stirred at rt for 2 h and evaporated. The residue was diluted with CH₂Cl₂ and then evaporated and re-evaporated three times to give the title compound as a colorless oil, 433 mg, 100% yield.


10 Step 3.



To a stirred solution of (*S*)-N-tert-butoxycarbonyl-isoleucine (372.6 mg, 1.61 mmol) and benzotriazol-1-yloxytritypyrrolidinophosphonium hexafluorophosphate (1.25


- 15 g, 2.42 mmol) in CH₂Cl₂ (6 mL) under nitrogen at rt was added 4-methylmorpholine (NMM) (0.36 mL, 3.2 mmol). After 5 min, a solution of Step 2 compound (433 mg, 1.61 mmol) and NMM (0.27 mL, 2.4 mmol) in CH₂Cl₂ (1 mL) was added. After addition, the reaction mixture was stirred 20 under nitrogen at room temperature overnight. The reaction mixture was diluted with CH₂Cl₂ (40 mL) and washed with 4% KHSO₄ (10 mL), aqueous NaHCO₃ (10 mL) and brine (10 mL), dried (Na₂SO₄) and evaporated. Purification by flash chromatography (1:4 EtOAc/hexane) 25 gave the title compound as a colorless oil, 530 mg, 89% yield.

Step 4



To a stirred solution of Step 3 compound (530 mg, 1.44 mmol) in MeOH (4 mL) and H₂O (4 mL) at rt was added LiOH-H₂O (91 mg, 2.16 mmol). The reaction mixture was stirred at rt overnight and evaporated. Water (10 mL) was added to the residue and extracted with Et₂O (2 x 10 mL). The aqueous layer was acidified to ~pH 4 by adding 4% KHSO₄ dropwise. The milky solution was extracted with EtOAc (15 mL x 3). Combined EtOAc layers were washed with brine, dried over Na₂SO₄ and evaporated to give the title compound as a white solid, 440 mg, 90% yield.


Step 5



To a stirred solution of Step 4 compound (300 mg, 0.88 mmol) in THF (6 mL) at -15°C under nitrogen, was added 4-methylmorpholine (0.12 mL, 1.06 mmol) and then isobutyl chloroformate (0.13 mL, 0.97 mmol) over 2 min. White precipitate was formed. The reaction mixture was stirred at -15°C under nitrogen for 25 min and a solution of NH₃ in dioxane (8.8 mL, 4.4 mmol) was added. The reaction mixture was stirred at -15°C for 30 min, warmed to rt and stirred at rt overnight. The reaction mixture was quenched by 4% KHSO₄ to ~pH 4 and extracted with EtOAc (20 mL x 3). The extracts were combined, washed with brine


(10 mL) dried (Na_2SO_4) and evaporated. Purification by flash column chromatography (1:1 EtOAc/hexane) gave the title compound as a white foam, 268 mg, 90% yield.

5 Step 6



To a stirred solution of Step 5 compound (248 mg, 1.38 mmol) and imidazole (94 mg, 1.38 mmol) in dry pyridine (12 mL) at -35°C under nitrogen was added POCl_3 (0.26 mL, 10 mmol) dropwise. The reaction mixture was stirred between -35°C to -20°C for 1 h and evaporated. CH_2Cl_2 (10 mL) was added and white precipitates were formed. After filtration, the filtrate was concentrated and purified by flash chromatography (2:5 EtOAc/hexane) to give the title compound as a colorless oil, 196 mg, 88% yield.

Step 7




To a stirred solution of Step 6 compound (130 mg, 0.4 mmol) in CH_2Cl_2 (2 mL) at rt was added TFA (2 mL). The reaction mixture was stirred at rt for 2 h. The reaction mixture was added slowly to a pre-cooled slurry of NaHCO_3 (3.8 g) in H_2O (3 mL). The mixture was extracted with CH_2Cl_2 (6 mL x 5), and the combined CH_2Cl_2 layers were evaporated and purified by preparative HPLC to give the title compound as a white powder, 77 mg. 57% yield, mp =


141-143°C. LC/MS gave the correct molecular ion $[(M+H)^+ = 222]$ for the desired compound.

Example 2

5




Step 1




Step 1 title compound was synthesized by following the literature procedure. [Stephen Hanessian, Ulrich Reinhold, Michel Saulnier, and Stephen Claridge; Bioorganic & Medicinal Chemistry Letters 8 (1998) 2123-2128.]


15 Step 2



The title compound was prepared from Step 1 compound, employing the same procedure as that described for Example 1, Steps 2-6. LC/MS gave the correct molecular ion $[(M+H)^+ = 222]$ for the desired compound.

Example 3


Step 1



5


Step 1 title compound was prepared by following the literature procedure. [Willy D. Kollmeyer, U.S. Patent 4,183,857.] .

10 Step 2



To a stirred solution of (*S*)-N-tert-butoxycarbonyl-isoleucine (231 mg, 1 mmol) and benzotriazol-1-yloxytritypyrrolidinophosphonium hexafluorophosphate (780 mg, 1.5 mmol) in CH₂Cl₂ (6 mL) under nitrogen at rt was added 4-methylmorpholine (0.33 mL, 3 mmol). After 5 min, Step 1 compound (120 mg, 1 mmol) was added in one portion. The reaction mixture was stirred under nitrogen at rt overnight and then diluted with CH₂Cl₂ (30 mL), washed with 4.1% KHSO₄ (10 mL), aqueous NaHCO₃ (10 mL), brine (10 mL), dried (Na₂SO₄) and evaporated. Purification by flash chromatography on silica gel (2.4 x 20 cm column, 1:3 EtOAc/hexane) gave the title compound as a colorless oil, 290 mg, 90% yield. LC/MS gave the correct molecular ion [(M+H)⁺ = 297] for the desired compound.


Step 3



The reaction mixture of Step 2 compound (220 mg, 0.74 mmol) and 4 M HCl in dioxane (1.5 mL, 6 mmol) was stirred at rt for 2 h and evaporated under reduced pressure. Et₂O was added to the residue and a precipitate was formed. Et₂O was decanted and this was done three times. The precipitate was dried *in vacuo* to give the title compound as a white powder, 130 mg (76% yield), mp 205–206°C. LC/MS gave the correct molecular ion [(M+H)⁺ = 197] for the desired compound.

Examples 4-4A

15




Step 1




Step 1 title compound, as a 1:1 ratio of enantiomers, was prepared by following the literature procedure. [Willy D. Kollmeyer, U.S. Patent 4,183,857.]

Step 2



- A slurry of (*S*)-*N*-tert-butoxycarbonyl-isoleucine (92.5 mg, 0.4 mmol), 1-[*(3*-(dimethylamino)propyl]-3-
5 ethylcarbodiimide (77 mg, 0.4 mmol) and HOAT (54.4 mg, 0.4 mmol) in $\text{ClCH}_2\text{CH}_2\text{Cl}$ (0.3 mL) was stirred under nitrogen at rt for 1 h, then Step 1 compound (22 mg, 0.2 mmol) was added, followed by Et_3N (0.015 mL, 0.1 mmol). The reaction mixture was stirred under nitrogen at rt
10 overnight and then diluted with CH_2Cl_2 (3 mL), washed with H_2O (1 mL), aqueous NaHCO_3 (1 mL) and brine (1 mL), dried (Na_2SO_4) and evaporated. Purification by flash chromatography on silica gel (2.4 x 12 cm column, 2:7 EtOAc/hexane) gave the title compound as a colorless oil,
15 33 mg, 51% yield. LC/MS gave the correct molecular ion [$(\text{M}+\text{H})^+ = 322$] for the desired compound.

Step 3




- 20 To a stirred solution of Step 2 compound (30 mg, 0.4 mmol) in CH_2Cl_2 (0.5 mL) at rt was added TFA (0.5 mL). The reaction mixture was stirred at rt for 2 h. The reaction mixture was added slowly to a precooled slurry of NaHCO_3 (0.8 g) in H_2O (1 mL). The mixture was
25 extracted with CH_2Cl_2 (2 mL x 5), and combined CH_2Cl_2 layers were evaporated and purified by preparative HPLC to give the title compounds as a 1:1 ratio of


diastereomers, 22 mg, 73% yield. LC/MS gave the correct molecular ion [$(M+H)^+ = 222$] for the desired compounds.

Examples 5-5A

5



and




Step 1



To a solution of Example 4, Step 1 compound (150 mg, 1.39 mmol) in 2-propanol (0.8 mL), was added NaCN (40 mg, 1.0 mmol). The reaction mixture was heated to reflux for 3 h. After cooling to rt, the reaction mixture was evaporated and then slurried in Et₂O (5 mL). After filtration, the filtrate was evaporated to give Example 4 Step 1 compounds and Example 5 Step 1 compounds (140 mg, 93%) as a 2:1 mixture of diastereomers, each as a racemic mixture.

Step 2



20


A slurry of (S)-N-tert-butoxycarbonyl-isoleucine (595 mg, 2.57 mmol), 1-[(3-(dimethyl)amino)propyl]-3-ethylcarbodiimide (493 mg, 2.57 mmol) and 1-hydroxy-7-azabenzotriazole (350 mg, 2.57 mmol) in $\text{ClCH}_2\text{CH}_2\text{Cl}$ (2 mL) was stirred under nitrogen at rt for 1 h, then Step 1 compound mixture (139 mg, 1.28 mmol) was added. The

reaction mixture was stirred under nitrogen at rt overnight and then diluted with CH₂Cl₂ (30 mL), washed with H₂O (10 mL), saturated aqueous NaHCO₃ (10 mL) and brine (10 mL), dried (Na₂SO₄) and evaporated.


- 5 Purification by flash chromatography on silica gel (2.4 x 20 cm column, 1:3 EtOAc/hexane) gave the Example 4, Step 2 compound (260 mg), and the title compounds (105 mg) as a ratio of 1:1 diastereomers. LC/MS gave the correct molecular ion [(M+H)⁺ = 322] for the desired compounds.

10

Step 3



and




- To a stirred solution of Step 2 compounds (104 mg, 0.32 mmol) in CH₂Cl₂ (1 mL) at rt was added TFA (1 mL). The reaction mixture was stirred at rt for 2 h. The reaction mixture was added slowly to a precooled slurry of NaHCO₃ (2 g) in H₂O (2 mL). The mixture was extracted with CH₂Cl₂ (4 mL x 4), and combined CH₂Cl₂ layers were evaporated and purified by preparative HPLC to give the title compound Example 5 (36 mg) and Example 5A (36 mg). LC/MS gave the correct molecular ion [(M+H)⁺ = 222] for the desired compounds.

Example 6

- 25 **General Method A:** Parallel array synthesis methods for preparation of inhibitors from commercially available amino acids. As shown in Scheme 3, the ester 11, described in Example 1 Step 1, was saponified to the acid with LiOH in THF/H₂O and converted to the amide 12 by treatment with isobutyl chloroformate/NMM followed by ammonia in dioxane. The Boc protecting group was removed under acidic conditions using TFA in methylene chloride to give 13. The TFA salt was coupled to Boc-t-


butylglycine using either EDAC/HOBT/DMF or EDAC/DMAP/CH₂Cl₂, to give 14. The amide was dehydrated to the nitrile 15 using POCl₃/imidazole in pyridine at -20°C and finally deprotected with TFA in CH₂Cl₂ at ambient 5 temperature to afford the target 16.

Scheme 3, General Method A (Examples 6-27)




a. LiOH in THF/H₂O or MeOH/H₂O b. i-BuOCOCl/NMM or i-BuOCOCl/TEA at -30C or EDAC, then NH₃ in dioxane or Et₂O at RT c. TFA, CH₂Cl₂, RT d. Boc-t-butylglycine and PyBop/ NMM or EDAC, DMAP, CH₂Cl₂ e. POCl₃, pyridine, imidazole, -20C f. TFA, CH₂Cl₂, RT

10



Step 1




15

To a stirred solution of Example 1 Step 1 compound (1.40 g, 5.49 mmol) in 40 mL of a 1:1 methanol:water solution at rt was added lithium hydroxide (0.20 g, 8.30 mmol). The reaction mixture was stirred at rt for 18 h and then


heated to 50°C for 2 h. The mixture was diluted with equal volumes of ether and water (50 mL) and then acidified with KHSO₄ to pH 3. The milky solution was extracted with ether (3 X 20 mL). The combined ether layers were dried over Na₂SO₄ and evaporated. The residue was stripped from toluene (2 X 10 mL) and dried under reduced pressure to give the title compound as a thick syrup, 1.20 g, 96%.

10 Step 2




To a stirred solution of Step 1 compound (1.20 g, 5.28 mmol) in THF (20 mL) at -15°C under nitrogen was added 4-methylmorpholine (0.71 mL, 6.50 mmol) and then isobutyl chloroformate (0.78 mL, 6.00 mmol) over 5 min. The reaction was stirred at -15°C for 30 min, cooled to -30°C and treated with a solution of NH₃ in dioxane (50 mL, 25 mmol). The reaction mixture was stirred at -30°C for 30 min, warmed to rt and stirred overnight. The reaction mixture was quenched with citric acid solution (pH 4) and extracted with ether (3 X 50 mL). The combined organic fractions were washed with brine, dried over Na₂SO₄ and concentrated. Purification by flash column chromatography on silica gel with EtOAc gave the Step 2 compound, 1.00 g, 84%.

Step 3



To a stirred solution of Step 2 compound (0.90 g, 4.00 mmol) in CH₂Cl₂ (3 mL) at 0°C was added TFA (3 mL). The reaction mixture was stirred at 0°C for 18 h. The reaction mixture was concentrated under reduced pressure 5 to produce title compound in the form of a thick oil, 0.98 g, 100%. The oil gradually solidified upon prolonged standing.

Step 4




10

An oven-dried 15-mL test tube was charged with Step 3 compound (56 mg, 0.22 mmol), N-tert-butoxycarbonyl-(L)-tert-leucine (53 mg, 0.23 mmol), dimethylaminopyridine (0.11 g, 0.88 mmol), and CH₂Cl₂ (4 mL). The tube was 15 sealed under nitrogen atmosphere and treated with 1-[(3-(dimethyl)amino)propyl]-3-ethylcarbodiimide (84 mg, 0.44 mmol). The mixture was placed in a shaker and vortexed overnight. The product was purified by solid phase extraction using a United Technology SCX column (2 g of 20 sorbent in a 6 mL column) by loading the material on a SCX ion exchange column and successively washing with CH₂Cl₂ (5 mL), 30% methanol in CH₂Cl₂ (5 mL), 50% methanol in CH₂Cl₂ (5 mL) and methanol (10 mL). The product containing fractions were concentrated under reduced 25 pressure to give the desired amide. Further purification by reverse phase preparative column chromatography on a YMC S5 ODS 20 X 250 mm column gave the title compound, 50 mg (68% yield). Purification conditions: Gradient elution from 30% methanol/water/0.1 TFA to 90% 30 methanol/water/0.1 TFA over 15 min. 5 min. hold at 90%

methanol/water/0.1 TFA. Flow rate: 20 mL/min. Detection wavelength: 220. Retention Time: 14 min.


Step 5



5

An oven-dried 15-mL test tube was charged with Step 4 compound (50 mg, 0.15 mmol), imidazole (31 mg, 0.46 mmol), and pyridine (1 mL). The tube was sealed under nitrogen atmosphere and cooled to -30°C. Slow addition of 10 POCl_3 (141 mg, 88 μL , 0.92 mmol) gave after mixing a thick slurry. The tube was mixed at -30°C for 3 h and the volatiles evaporated. The product was purified by solid phase extraction using a United Technology silica extraction column (2 g of sorbent in a 6 mL column) by 15 loading the material on a silica column and successively washing with CH_2Cl_2 (5 mL), 5% methanol in CH_2Cl_2 (5 mL), 7% methanol in CH_2Cl_2 (5 mL) and 12% methanol in CH_2Cl_2 (10 mL). The product containing fractions were pooled and concentrated under reduced pressure to give the title 20 compound, 46 mg, 96%.


Step 6



An oven-dried 15-mL test tube was charged with Step 5 25 compound (0.45 mg, 0.14 mmol), CH_2Cl_2 (1 mL), and TFA (1 mL). The reaction mixture was vortexed for 40 min at rt,

diluted with toluene (4 mL) and concentrated under reduced pressure to a thick oil. The product was purified by reverse phase preparative column chromatography on a YMC S5 ODS 20 X 250 mm column to give 5 the Example 6 compound, 14 mg, .35%. Purification conditions: gradient elution from 10% methanol/water/0.1 TFA to 90% methanol/water/0.1 TFA over 18 min; 5 min hold at 90% methanol/water/0.1 TFA. Flow rate: 20 mL/min. Detection wavelength: 220. Retention Time: 10 min.


10 Examples 7-27 were prepared from amino acids available from commercial sources according to the procedure in Example 6.

Table 1


Example	R	[M + H]
7		302
8		295
9		240
10		222
11		222
12		222
13		208
14		270

15		222
16		206
17		256
18		268
19		220
20		220
21		210
22		262
23		242

24		210
25		281
26		281
27		272


Example 27

5 Step 1



(2*S*,4*S*,5*S*)-4,5-methano-L-proline carboxylamide, TFA salt
 10 (53 mg, 0.22 mmol) was coupled to N-Boc-L-Tyrosine-benzyl ether (82 mg, 0.22 mmol) using PyBop (172 mg, 0.33 mmol) and N-methylmorpholine (67 mg, 0.66 mmol) in 4 mL CH₂Cl₂. The reaction stirred for 16 h, was taken up in EtOAc, washed with H₂O, 1N aqueous HCl, brine, then evaporated
 15 and purified by silica gel flash chromatography to give the coupled product (FAB MH⁺ 480).


Step 2



5

The Step 1 amide was dehydrated to the nitrile using the general method C (which follows Example 29) (FAB MH⁺ 462).

10 Step 3



15 The Step 2 benzyl ether was cleaved by catalytic hydrogenolysis using 10% palladium on carbon and 1 atmosphere hydrogen gas in MeOH at rt for 1.5 h. The reaction was filtered through celite and concentrated to an oil and taken on without further purification (FAB MH⁺ 372).


20

Step 4



Step 3 N-[N-Boc-L-Tyrosine-]-(2S,4S,5S)-2-cyano-4,5-methano-L-proylamide was dissolved in CH₂Cl₂ and TFA was added at rt. The reaction stirred for 1 h and was evaporated and purified by preparative HPLC as described 5 in general method B (set out following Example 29) to afford the title compound (FAB MH⁺ 272).

Example 28




10

The title compound was prepared by coupling (2S,4S,5S)-4,5-methano-L-proline carboxylamide, TFA salt described in Example 6 Step 3 compound with N-(tert-butyloxycarbonylhydroxyvaline. After hydroxyl protection with triethylsilyl chloride and dehydration of the amide with POCl₃/imidazole in pyridine and deprotection (N-terminal nitrogen and valine hydroxyl) with TFA using general 15 method C (FAB MH⁺ 224), the title compound was obtained.


20

Example 29



Step 1


25



N-Boc-L-homoserine (1.20 g, 5.47 mmol) upon treatment with tert-butyldimethylsilyl chloride (1.67 g, 11.04

mmol) and imidazole (938 mg, 13.8 mmol) in THF (17 mL) was stirred as thick slurry for 48 h under N₂. The solvent was evaporated, and the crude material was dissolved in MeOH (10 mL). The resulting solution was 5 stirred at rt for 2 h. The solvent was evaporated, and the crude material was diluted with CH₂Cl₂ (50 mL) and treated with 0.1N HCl (2x10 mL). The CH₂Cl₂ layer was washed with brine and dried over MgSO₄. Removal of the volatiles gave title compound as an oil (1.8 g), which 10 was used without further purification (LC/Mass, + ion): 334 (M+H).


Step 2



15


To a stirred solution of Step 1 compound (333 mg, 1.0 mmol) in 6 mL of CH₂Cl₂ was added 1-[3-(dimethylamino)-propyl]-3-ethylcarbodiimide hydrochloride (256 mg, 1.32 20 mmol). The solution was then stirred at rt for 30 min, followed by addition with Example 6 Step 3 amine TFA salt (160 mg, 0.66 mmol) and 4-(dimethylamino)pyridine (244 mg, 2.0 mmol). The solution was then stirred at rt overnight. The mixture was diluted with CH₂Cl₂ (5 mL) and 25 washed sequentially with H₂O, 10% citric acid, brine, then dried over Na₂SO₄ and evaporated to give the title compound (350 mg) which was used without further purification (LC/Mass, + ion): 442 (M+H).

Step 3



- 5 An oven-dried 10-mL round bottomed flask was charged with Step 2 compound (350 mg, 0.79 mmol), imidazole (108 mg, 1.58 mmol), pyridine (3 mL). The flask under argon was cooled to -30°C. Slow addition of POCl₃ (0.30 mL, 3.16 mmol) gave after mixing a thick slurry. The slurry was
10 mixed at -30°C for 3 h and the volatiles evaporated. Dichloromethane (5 mL) was then added and the insoluble solid was removed by filtration. The organic layer was washed with H₂O, 10% citric acid, brine and dried over Na₂SO₄. Removal of solvent gave crude desired nitrile
15 (330 mg) (LC/Mass, + ion): 424 (M+H).


Step 4




- 20 Trifluoroacetic acid (3.3 mL) was added to a stirred solution of Step 3 compound (330 mg, 0.58 mmol) in 3.3 mL CH₂Cl₂. The solution was then stirred at rt for 30 min, a few drops of water were added and the mixture mixture
25 stirred for 0.5 h. The mixture was diluted with CH₂Cl₂ (5 mL) and concentrated under reduced pressure to a thick oil. The product was purified by reverse phase preparative column chromatography on a YMC S5 ODS 20x100 mm column to give the title compound, 59 mg, 17%.
30 Purification conditions: gradient elution from 10% methanol/water/0.1 TFA to 90% methanol/water/ 0.1 TFA

over 15 min; 5 min hold at 90% methanol/water/0.1 TFA.
Flow rate: 20 mL/min. Detection wavelength: 220.
Retention Time 10 Min. (LC/Mass, + ion): 210 (M+H).

5 **General Method B:** Claisen rearrangement sequence to Boc-protected amino acids.



- 10 General method B affords the quaternary Boc-protected amino acids. Examples 30-47 contain the vinyl sidechain by coupling amino acids of which Scheme 4, compound **20** is representative. Cyclopentanone was olefinated under Horner-Emmons conditions to afford **17** which was reduced
15 to the allylic alcohol **18** using DIBAL-H in toluene -78 °C to rt. Allylic alcohol **18** was esterified with N-Boc glycine using DCC/DMAP in CH₂Cl₂ to give **19**. Glycine ester **19** was subjected to a Lewis acid mediated Claisen rearrangement by complexation with anhydrous zinc
20 chloride and deprotonation at -78°C with lithium diisopropylamide followed by warming to ambient temperature to afford **20**.

Scheme 4, General Method B, Examples 30-47

a. Triethylphosphonoacetate, NaH, THF O C to RT b. DIBAL-H, toluene, -78 C to RT c. N-Boc glycine, DCC, DMAP, CH_2Cl_2 , RT
d. ZnCl_2 , THF, LDA, -78 C to RT

Step 1

5 Cyclopentylideneacetic acid ethyl ester.

To a flame-dried 500-mL round-bottomed flask containing NaH (5.10 g of a 60% dispersion in mineral oil, 128 mmol, 1.10 equiv) in 120 mL anhydrous THF at 0°C under argon was 10 added triethylphosphonoacetate (25.6 mL, 128 mmol, 1.10 equiv) dropwise through an addition funnel. The mixture was allowed to warm to rt, stirring for an additional 1 h. A solution of cyclopentanone (10.3 mL, 116 mmol) in 10 mL anhydrous THF was added dropwise over 20 min 15 through an addition funnel, and the mixture was allowed to stir at rt for 2.5 h. Ether (200 mL) and water (100 mL) were then added, and the layers were separated. The organic phase was washed successively with water (100 mL) and brine (100 mL), dried (Na_2SO_4), and concentrated under 20 reduced pressure, giving 17.5 g (98%) of the desired ester as a colorless oil.

Step 2

2-Cyclopentylideneethanol.

To a flame-dried 500-mL round-bottomed flask containing

5 cyclopentylideneacetic acid ethyl ester (17.5 g, 113 mmol) in 100 mL anhydrous toluene at -78°C under argon was added DIBAL-H (189 mL of a 1.5 M solution in toluene, 284 mmol, 2.50 equiv) dropwise over a 30 min period through an addition funnel, and the mixture was then allowed to


10 warm to rt, stirring for 18 h. The reaction mixture was then recooled to -78°C, and quenched by the careful addition of 30 mL anhydrous MeOH. Upon warming to rt, 1 N Rochelle's salt (100 mL) was added, and the mixture was stirred 90 min. The biphasic reaction mixture was then

15 diluted with Et₂O (200 mL) in a separatory funnel, and the layers were separated. The organic layer was then washed with brine (100 mL), dried (Na₂SO₄), and concentrated under reduced pressure. Purification by flash column chromatography (silica gel, CH₂Cl₂ / EtOAc, 10:1) gave

20 11.6 g (92%) of the desired allylic alcohol as a colorless oil.

Step 3

(2-Cyclopentylideneethyl)-N-(tert-Butyloxycarbonyl)
25 glycinate.




To a flame-dried 500-mL round-bottomed flask containing

30 N-(tert-butyloxycarbonyl)glycine (13.45 g, 76.75 mmol) in 100 mL CH₂Cl₂ at rt was added Step 2 compound (8.61 g, 76.75 mmol, 1.00 equiv) in 20 mL CH₂Cl₂, followed by dicyclohexylcarbodiimide (16.63 g, mmol, 1.05 equiv) in 80 mL CH₂Cl₂. To this reaction mixture was then added 4-

dimethylaminopyridine (0.94 mg, mmol, 0.10 equiv), and the mixture was allowed to stir overnight. The reaction mixture was then filtered through a medium sintered-glass funnel, rinsing with 100 mL CH₂Cl₂, and concentrated under reduced pressure. The crude product was then purified by flash chromatography (silica gel, hexanes/EtOAc, 20:1 to 1:1 gradient) to give 19.43 g (94%) of the desired glycinyl ester as a colorless oil.

10 Step 4

N-(tert-Butyloxycarbonyl)(1'vinylcyclopentyl)-glycine



15 A flame-dried 500-mL round-bottomed flask under argon was charged with ZnCl₂ (11.8 g, mmol, 1.20 equiv) and 20 mL toluene. The mixture was heated under vacuum with vigorous stirring to azeotrope off any traces of moisture 20 with the distilling toluene, repeating this process (2 x). The flask was then cooled to rt under argon, (2-cyclopentylideneethyl) N-(tert-butyloxycarbonyl)glycinate (19.36 g, 71.88 mmol) was added via cannula as a solution in 180 mL THF, and the mixture was then cooled to -78°C.

25 In a separate flame-dried 200-mL round-bottomed flask containing diisopropylamine (26.3 mL, mmol, 2.60 equiv) in 90 mL THF at -78°C was added n-butyllithium (71.89 mL of a 2.5 M solution in hexanes, mmol, 2.5 equiv), and the mixture was allowed to warm to 0°C for 30 min before

30 recooling to -78°C. The lithium diisopropylamine thus generated was then added via cannula to the ZnCl₂ ester mixture dropwise at a steady rate over 40 min, and the


resultant reaction mixture was allowed to slowly warm to rt and stir overnight. The yellow reaction mixture was then poured into a separatory funnel, diluted with 300 mL Et₂O, and the resultant organic solution was washed 5 successively with 300 mL 1N HCl and 300 mL brine, dried (Na₂SO₄), and concentrated under reduced pressure. Purification by flash chromatography (silica gel, 3% MeOH in CH₂Cl₂ with 0.5% HOAc) gave 17.8 g (92%) of the desired amino acid product as a white solid. (FAB MH⁺ 270).

10


Example 30

General Method C: Peptide coupling to 4,5-methanoprolinamide, amide dehydration and final deprotection.

15




The TFA salt of amide 13 was coupled to a variety of racemic quaternary protected amino acids using HOBT/EDC 20 in DMF at rt to give a D/L mixture of diastereomers at the N-terminal amino acid. The desired L diastereomer was chromatographically isolated either as the amide 21 or as the nitrile 22. Nitrile 22 was obtained by treatment of the amide with POCl₃/imidazole in pyridine at 25 -20°C. The final target 23 was obtained by deprotection under acidic conditions using TFA in CH₂Cl₂.

Scheme 5, General Method C

a. EDAC, HOBT, DMF b. POCl_3 , pyridine, imidazole, -20C c. TFA, CH_2Cl_2 , RT


Step 1

5




Example 6 Step 3 compound (877 mg, 3.65 mmol) and N-Boc cyclopentylvinylamino acid, described in Step 4 of 10 general method B (1.13 g, 4.20 mmol) were dissolved in 20 mL anhydrous DMF, cooled to 0°C and to this mixture was added EDAC (1.62 g, 8.4 mmol), HOBT hydrate (2.54 g, 12.6 mmol, and TEA (1.27 g, 12.6 mmol) and the reaction was allowed to warm to rt and stirred for 24 h. The reaction 15 mixture was taken up in EtOAc (100 mL), washed with H₂O (3 x 20 mL), dried (Na₂SO₄), and purified by silica gel flash column chromatography (100% EtOAc) to give 1.38 g (86%) of Step 1 compound (M⁺, 378).

Step 2



5 Step 1 compound (1.38 g, 3.65 mmol) and imidazole (497 mg, 7.30 mmol) were dried by toluene azeotrope (5 mL x 2), dissolved in 10 mL anhydrous pyridine, cooled to -30°C under nitrogen gas and POCl₃ (2.23 g, 14.60 mmol) was added by syringe. The reaction was complete after 1 h
 10 and was evaporated to dryness and the remainder purified by two sequential flash column chromatographies over silica gel. The first column (100% EtOAc) was used to isolate the mixture of diastereomers (1.15 g, 88%) from the by-products of the reaction. The second column
 15 (gradient of 25% EtOAc/hexanes to 50% EtOAc/hexanes) was run to resolve the mixture of diastereomers and provided 504 mg of the desired Step 2 nitrile (MH+360).

Step 3




20 Step 2 compound (32 mg, 0.09 mmol) was dissolved in 1 mL of CH₂Cl₂ and 1 mL of TFA was added and the reaction
 25 stirred for 30 min at rt and was evaporated to dryness. The product was purified by reverse phase preparative column chromatography on a YMC S5 ODS 20 X 250 mm column to give 12 mg of the TFA salt (lyophilized from water or isolated after evaporation of eluent and trituration with ether) the title compound. Purification conditions:
 30 gradient elution from 10% methanol/water/0.1 TFA to 90%

methanol/water/0.1 TFA over 18 min; 5 min. hold at 90% methanol/water/0.1 trifluoroacetic acid. Flow rate: 20 mL/min. Detection wavelength: 220.

- 5 Examples 30-39 were prepared by the methods outlined in General Method B and General Method C starting from cyclopentanone, cyclobutanone, cyclohexanone, cycloheptanone, cyclooctanone, cis-3,4-dimethylcyclopentanone, and 4-pyanone,
- 10 cyclopropaneethylhemiacetal, acetone, and 3-pentanone respectively.

Table 2



15


Example	R	MS [M + H]
30		260
31		246
32		274
33		288

34		302
35		288
36		276
37*		232
38		234
39		262


* Step 3 compound was prepared by the method described in Tetrahedron Letters 1986, 1281-1284.

Example 40

5




Step 1



Step 1 compound was prepared employing general method B starting from cyclopentanone and 2-fluoro-triethylphosphonoacetate instead of triethylphosphonoacetate.

5


Step 2




- 10 Title compound was prepared by the peptide coupling of Step 1 acid followed by dehydration and final deprotection as described in general method C [MS (M+H) 278].

15

Example 41



Step 1




20

Step 1 compound was prepared employing general method B starting from cyclobutanone and 2-fluoro-triethylphosphonoacetate instead of triethylphosphonoacetate.


25

Step 2




5 Title compound was prepared by the peptide coupling of Step 1 acid followed by dehydration and final deprotection as described in general method C. MS (M+H) 264.

10

Example 42

Step 1


15



Step 1 compound was prepared employing general method B starting from cyclopentanone and triethylphosphono-propionate instead of triethylphosphonoacetate.


20

Step 2




- 5 Title compound was prepared by the peptide coupling of Step 1 acid followed by dehydration and final deprotection as described in general method C. MS (M+H)
274

10

Example 43

Step 1


15



20

Step 1 compound was prepared employing general method B starting from cyclobutanone and triethylphosphono-propionate instead of triethylphosphonoacetate.

Step 2




- 5 Title compound was prepared by the peptide coupling of Step 1 acid followed by dehydration and final deprotection as described in general method C. MS (M+H) 260.

10

Example 44

- General Method D:** Oxidative cleavage of vinyl substituent by ozonolysis. The protected cyclopentylvinyl nitrile **22** was treated with ozone for 6-15 min and subjected to a reductive quench with sodium borohydride to furnish the hydroxymethyl analog **24** directly. This compound was deprotected under acidic conditions with TFA in CH₂Cl₂ at 0°C to give the target compound **25**.

20

Scheme 6, General Method D, Examples 44, 46, 48


- a. O₃, MeOH:CH₂Cl₂, 10:4, -78 C; then NaBH₄, -78 C to 0 C, 79%
 b. TFA:CH₂Cl₂, 1:2, 0 degrees C.

Step 1



Cyclopentylvinyl compound prepared in Step 2 of general
 5 method C (1.28 g, 3.60 mmol) was dissolved in 56 mL of a
 2:5 mixture of CH_2Cl_2 :methanol, cooled to -78°C and was
 treated with a stream of ozone until the reaction mixture
 took on a blue color, at which time, NaBH_4 (566 mg, 15.0
 mmol, 4.2 equiv) was added and the reaction was warmed to
 10 0°C . After 30 min, the reaction was quenched with 2 mL
 saturated aqueous NaHCO_3 and then warmed to rt. The
 reaction mixture was evaporated to dryness and taken up
 in EtOAc . A small amount of water was added to dissolve
 the inorganics and the layers separated. The EtOAc layer
 15 was dried (Na_2SO_4), filtered and evaporated to an oil that
 was purified by flash column chromatography on silica gel
 with EtOAc to give 922 mg (71%) of Step 1 compound.
 MS ($M+H$) 364.

20 Step 2



Step 1 compound (900 mg, 2.48 mmol) was dissolved in 60
 mL of CH_2Cl_2 , cooled to 0°C and treated with 20 mL of
 25 freshly distilled TFA. The reaction was complete in 80
 min and the mixture was evaporated to dryness and
 purified by preparative HPLC (YMC S5 ODS 30 x 100 mm, 18
 minute gradient 80% Solv A:Solv B to 100% Solv B, Solvent
 A = 10% MeOH-90% H_2O -0.1% TFA, Solvent B = 90% MeOH-10%


$\text{H}_2\text{O} - .1\%$ TFA, collected product from 5.1-6.5 min) to give, after lyophilization from water, 660 mg (71%) of title compound, TFA salt as a white lyophillate. ($\text{MH}^+ + 264$).

5

Example 45


General Method E: Oxidative cleavage of vinyl substituent by osmium tetroxide-sodium periodate followed by sodium borohydride reduction to alcohol. The cyclobutylololefin **26** was treated with osmium tetroxide and sodium periodate in THF:water, 1:1, and the intermediate aldehyde was isolated crude and immediately reduced with sodium borohydride to give **27** in 56% yield. Standard deprotection conditions using TFA afforded the target compound **28**.

15


Scheme 7, General Method E, Examples 45, 47

a. OsO_4 , $\text{THF:H}_2\text{O}$, 1:1; NaIO_4 ; workup, then NaBH_4 , MeOH , RT. 56%
 b. $\text{TFA:CH}_2\text{Cl}_2$, 1:2, 0 degrees C to RT.

20




Step 1



5 N-Boc protected cyclobutylvinyl compound (Example 31, prepared by general method C) (0.16 g, 0.46 mmol) was dissolved in 10 mL of a 1:1 mixture of THF:water and treated with OsO_4 (12 mg, catalyst) and NaIO_4 (0.59 g, 2.76 mmol, 6 equiv). After 2 h, the reaction mixture was
 10 diluted with 50 mL of ether and 10 mL of water. The layers were equilibrated and the organic fraction was washed one time with NaHCO_3 solution, dried over MgSO_4 and concentrated to give a dark oil. The oil was diluted with 10 mL of methanol and treated with NaBH_4 (0.08 g, 2.0
 15 mmol). The mixture turned very dark and after 30 min was diluted with ether and the reaction was quenched with aqueous NaHCO_3 solution. The mixture was equilibrated and layers separated. The organic fraction was washed with solutions of NaHCO_3 and 0.1 M HCl. The organics were
 20 dried (MgSO_4) and concentrated to give 90 mg (56%) of the Step 1 compound as a dark oil.


Step 2




Step 1 compound (90 mg, 0.26 mmol) was dissolved in 3 mL of CH₂Cl₂, cooled to 0°C and treated with 3 mL of freshly distilled TFA. The reaction was complete in 80 min and evaporated to dryness and purified by preparative HPLC 5 (YMC S5 ODS 30 x 100 mm, 10 minute gradient 100%A to 100%B, Solvent A = 10% MeOH-90%H₂O-0.1% TFA, Solvent B = 90% MeOH-10% H₂O -0.1% TFA, to give, after removal of water, 50 mg (60%) of title compound. (MH+250).

10


Table 3



Example	R	Method of Preparation	[M + H]
44		Ozonolysis/borohydride	264
45		Osmium/periodate/borohydride	250
46		Ozonolysis/borohydride	278
47		Osmium/periodate/borohydride	292
48		Ozonolysis/borohydride	292

Example 49


5 Step 1



- Part A. A 50-mL flask was charged with dihydro-4,4-dimethyl-2,3-furandione (5.0 g, 39.0 mmol), acetic acid (10 mL), sodium acetate (3.82 g, 39.0 mmol) and hydroxylamine hydrochloride (2.71 g, 39.0 mmol). The reaction mixture was stirred for 2 h at rt and concentrated under reduced pressure to remove most of the acetic acid. The remainder was poured into water (100 mL) and the aqueous phase extracted with EtOAc (3 X 40 mL). The organics were dried over Na₂SO₄ and concentrated to a colorless oil which solidified on standing.
- Part B. A 200-mL round bottomed flask was charged with Part A solid (@ 39 mmol) and diluted with 80 mL of ethanol and 39 mL of 2N HCl (78 mmol). The mixture was treated with 1.0 g of 5% Pd/carbon and the mixture degassed. The flask was placed under an atmosphere of H₂ for 8 h. The mixture was filtered through celite and the filtrate concentrated to an off white solid.

Part C. A 250-mL round bottomed flask was charged with Part B solid and diluted with THF (50 mL) and water (15 mL). The mixture was treated with di-tert-butyl dicarbonate (12.7 g, 117 mmol) and sodium bicarbonate (10.0 g, 117 mmol). After 4 h of stirring the mixture was diluted with 50 mL of ether and 50 mL of water. The layers were separated and the organic fraction dried over MgSO₄ and concentrated. The residue was purified by flash column chromatography on silica gel with 30% EtOAc in hexanes to give 2.00 g (22% overall) of Step 1 compound as a white solid.

Step 2




To a stirred solution of Step 1 compound (1.00 g, 3.80 mmol) in THF (20 mL) at rt under nitrogen was added LiOH hydrate (0.16 g, 3.80 mmol) and then water (5 mL). The reaction was stirred at 40°C for 0.5 h and then cooled to 20 rt. The mixture was concentrated to dryness and the remainder was stripped from THF (2X), toluene (2X) and THF (1X). The remaining glass was diluted with 5 mL of THF and treated with imidazole (0.63 g, 9.19 mmol) followed by t-butyl-dimethylsilyl chloride (1.26 g, 8.36 mmol). The reaction was stirred overnight and quenched with 10 mL of methanol. After 1 h of stirring the mixture was concentrated. An additional portion of methanol was added and the mixture concentrated. The oil was diluted with ether and 0.1 N HCl (pH 2). The layers 25 were equilibrated and aqueous drawn off. The organic 30

fraction was dried over MgSO₄ and concentrated to give 1.25 g (83%) of Step 2 compound as a colorless glass.

Step 3


5



The Title compound was prepared by the peptide coupling of Step 2 carboxylic acid with Example 6 Step 3 amine, followed by dehydration and deprotection as outlined in
10 General Method C. MS (M+H) 238.

General Method F: Catalytic Hydrogenation of vinyl substituent. As shown in Scheme 8, the protected vinyl substituted amino acid **20** was transformed to the
15 corresponding saturated analog **29** by catalytic hydrogenation using 10% Pd/C and hydrogen at atmospheric pressure.

Scheme 8, General Method F, Examples 50-56



20


Step 1.

The N-(tert-Butyloxycarbonyl) (1'vinylcyclopentyl)glycine (2.23 g, 8.30 mmol) was dissolved in 50 mL MeOH and placed in a hydrogenation vessel purged with argon. To
25 this mixture was added 10% Pd-C (224 mg, 10% w/w) and the reaction stirred under 1 atm H₂ at rt for 12 h. The reaction was filtered through celite and concentrated and

purified by flash column chromatography on silica gel with 1:9 methanol:CH₂Cl₂ to give the Step 1 compound as a glass. (FAB MH⁺ 272)


- 5 Examples 50-56 were prepared by the peptide coupling of amino acids (where the vinyl substituent has been hydrogenated according to general method F) followed by dehydration and deprotection as described in general method C.

10

Table 4

Example	R1, R2	MS [M + H]
50	Cyclopentyl	262
51	cyclobutyl	248
52	cycloheptyl	290
53	4-pyranyl	278
54	methyl, methyl	236
55	ethyl, ethyl	264
56	methyl, ethyl	250


15

Example 57

The title compound in Example 57 was prepared by the peptide coupling of the isopropyl cyclobutane amino acid



(where the olefin substituent has been hydrogenated according to general method F) followed by dehydration and deprotection as described in general method C.

5

Example 58

- The title compound in Example 58 was prepared by the peptide coupling of the isopropyl cyclopentane amino acid
10 (where the olefin substituent has been hydrogenated according to general method F) followed by dehydration and deprotection as described in general method C. MS (M+H) 276
- 15 **General Method G:** L-Amino acids synthesized by Asymmetric Strecker Reaction. Commercially available adamantlyl carboxylic acid was esterified either in MeOH with HCl at reflux or using trimethylsilyldiazomethane in Et₂O/methanol to give 30. The ester was reduced to the
20 alcohol 31 with LAH in THF and then subjected to a Swern oxidation to give aldehyde 32. Aldehyde 32 was transformed to 33 under asymmetric Strecker conditions with KCN, NaHSO₃, and R-(--)-2-phenylglycinol. The nitrile of 33 was hydrolyzed under strongly acidic conditions
25 using 12M HCl in HOAc to give 34. The chiral auxiliary was removed by catalytic reduction using Pearlman's catalyst in acidic methanol under 50 psi hydrogen to give 35 and the resulting amino group was protected as the t-butylcarbamate to give 36.

30

Scheme 9, General Method G, Examples 59-64**Step 1**

5

Adamantane-1-carboxylic acid (10.0 g, 55 mmol, 1 equiv) was dissolved in a mixture of Et₂O (160 mL) and MeOH (40 mL), and was treated with trimethylsilyl diazomethane (2.0 M in hexane, 30 mL, 60 mmol, 1.1 equiv) and stirred at rt for 3 h. The volatiles were then removed by rotary evaporation and the product purified by flash column chromatography on silica gel (5x15 cm) with 40% CH₂Cl₂/hexanes to give the product as a white crystalline solid (10.7 g, 100%).

15

Step 2



- Step 1 compound (10.7 g, 0.055 mmol, 1 equiv) was dissolved in anhydrous THF (150 mL) under argon and was treated with a solution of LiAlH₄ (1 M in THF, 69 mL, 69 mmol, 1.25 equiv). After stirring at rt for 1.5 h, the reaction was cooled to 0°C and quenched sequentially with H₂O (5.1 mL), 15% aq NaOH (5.1 mL), and H₂O (10.2 mL).
- After stirring at rt for 15 min, the slurry was vacuum filtered, and the solids washed with EtOAc (2x100 mL). The filtrate was concentrated by rotary evaporation and the resulting solid purified by flash column chromatography on silica gel (5x15 cm) with 10% EtOAc/CH₂Cl₂. This afforded the Step 2 product as a white solid (8.74 g, 96%).


Step 3



- An oven-dried 3-neck flask equipped with 125-mL addition funnel was charged with anhydrous CH₂Cl₂ (150 mL) and anhydrous DMSO (10.3 mL, 0.145 mol, 2.5 equiv) under argon atmosphere and cooled to -78°C. Slow dropwise addition of oxalyl chloride (6.7 mL, 0.0768 mol, 1.32 equiv) followed by stirring for 15 min provided an activated DMSO adduct. This was treated with a solution of Step 2 compound (9.67 g, 58.2 mmol, 1 equiv) in dry CH₂Cl₂ (75 mL) and the reaction allowed to stir for 1 h.
- The resulting white mixture was then treated dropwise with triethylamine (40.5 mL, 0.291 mol, 5 equiv). After


30 min, the cooling bath was removed, and the reaction quenched sequentially with cold 20% aq KH_2PO_4 (25 mL) and cold H_2O (150 mL). After stirring at rt for 15 min the mixture was diluted with Et_2O (400 mL) and the layers were
5 separated. The organics were washed organic with cold 10% aq KH_2PO_4 (3x150 mL) and satd aq NaCl (100 mL). The organics were dried (Na_2SO_4), filtered and concentrated. The residue was purified by flash column chromatography
10 on silica gel (5x10 cm) with CH_2Cl_2 to give the Step 3 compound as a white solid (9.40 g, 98%).

Step 4



15 Step 3 compound (9.40 g, 57 mmol, 1 equiv) was suspended in H_2O (145 mL) and cooled to 0°C. The mixture was treated with NaHSO_3 (5.95 g, 57 mmol, 1 equiv), KCN (4.0 g, 59 mmol, 1.04 equiv), and a solution of (*R*)-(-)-phenylglycinol (8.01 g, 57 mmol, 1 equiv) in MeOH (55 mL). The resulting mixture was stirred at rt for 2 h, then refluxed for 16 h. The mixture was cooled to rt, and 200 mL of EtOAc added. After mixing for 15 min the layers were separated. The aqueous fraction was extracted with EtOAc . The combined EtOAc extracts were
20 washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered and the filtrate concentrated. The product was
25 purified by flash column chromatography on silica gel (6.4x20 cm) with 20% $\text{EtOAc}/\text{hexanes}$ to give the desired (R,S) product as a white solid (11.6 g, 37.4 mmol, 65%):
30 MS m/e 311 ($\text{M}+\text{H})^+$.

Step 5



The Step 4 nitrile (5.65 g, 18 mmol) was heated in conc.
 5 HCl (120 mL) and HOAc (30 mL) at 80°C for 18 h, at which time the reaction was cooled in an ice bath. Vacuum filtration of the resulting precipitate afforded the desired product as a white solid (5.21 g, 14 mmol, 78%).
 MS m/e 330 (m+H)⁺.


10

Step 6



The Step 6 compound (5.21 g, 14 mmol) was dissolved in
 15 MeOH (50 mL) and HOAc (10 mL), and hydrogenated with H₂ (50 psi) and Pearlman's catalyst (20% Pd(OH)₂, 1.04 g, 20% w/w) for 18 h. The reaction was filtered through a PTFE membrane filter and the catalyst washed with MeOH (3x25 mL). The filtrate was concentrated by rotary evaporation
 20 to afford a white solid. The product was used in Step 7 without further purification.

Step 7




25


The crude Step 6 compound (@ 14 mmol) was dissolved in anhydrous DMF (50 mL) under argon and treated with K₂CO₃

(5.90 g, 42 mmol, 3 equiv) and di-*tert*-butyldicarbonate (3.14 g, 14 mmol, 1 equiv) under argon at rt. After 19 h, the DMF was removed by rotary evaporation (pump) and the residue dried further under reduced pressure. The 5 residue was mixed with H₂O (100 mL) and Et₂O (100 mL), the layers separated, and the alkaline aqueous with Et₂O (2x100 mL) to remove the by-product from the hydrogenolysis step. The aqueous was cooled to 0°C, diluted with EtOAc (200 mL), and stirred vigorously while 10 carefully acidifying the aqueous to pH 3 with 1N aq HCl. The layers separated and the aqueous extracted with EtOAc (100 mL). The combined EtOAc extracts were washed with brine (50 mL), dried (Na₂SO₄), filtered and the filtrate concentrated by rotary evaporation. The residue was 15 purified by SiO₂ flash column (5x12 cm) with 5% MeOH/CH₂Cl₂ + 0.5% HOAc. The product was chased with hexanes to afford the product as a white foam (4.07 g, 13 mmol, 92%): MS m/e 310 (m+H)⁺.


20

Example 59

The title compound in Example 59 was prepared by the peptide coupling of the Step 7 compound in general method 25 G followed by dehydration and deprotection as described in general method C. MS m/e 300 (m+H)⁺.

Example 60


Step 1



5

A solution of KMnO_4 (337 mg, 2.13 mmol, 1.1 equiv) in 2% aq KOH (6 mL) was heated to 60°C and Step 7 compound in general method G (600 mg, 1.94 mmol, 1 equiv) was added 10 in portions, and heating increased to 90°C. After 1.5 h, the reaction was cooled to 0°C, EtOAc (50 mL) was added, and the mixture was carefully acidified to pH 3 with 1N HCl. The layers were separated and the aqueous was extracted with EtOAc (50 mL). The combined organic extracts were washed with brine, dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash column chromatography on silica gel (3.8x15 cm) with 2% (200 mL), 3% (200 mL), 4% (200 mL), and 5% (500 mL) $\text{MeOH}/\text{CH}_2\text{Cl}_2 + 0.5\%$ HOAc. After isolation of the 20 product, the material was chased with hexanes to afford a white solid (324 mg, 51%): MS m/e 326 ($\text{m}+\text{H}$)⁺.

Step 2




25

The Step 1 compound (404 mg, 1.24 mmol, 1 equiv) was dissolved in anhydrous DMF (10 mL) under argon and cooled to 0°C. The following were added in order: Example 6 Step 3 salt (328 mg, 1.37 mmol, 1.1 equiv), HOBT (520 mg, 5.85 mmol, 3.1 equiv), EDAC (510 mg, 2.61 mmol, 2.1 equiv), and TEA (0.54 mL, 3.85 mmol, 3.1 equiv). The reaction mixture was allowed to warm to rt overnight and the DMF removed by rotary evaporation (pump). The remainder was dried further under vacuum. The residue 10 was dissolved in EtOAc (100 mL), washed with satd aq NaHCO₃ (50 mL) and satd aq NaCl (25 mL), dried over anhydrous Na₂SO₄, filtered and concentrated by rotary evaporation. The product was purified flash column chromatography on silica gel (3.8x15 cm) with a gradient 15 of 6% (200 mL), 7% (200 mL), and 8% (500 mL) MeOH/CH₂Cl₂ to give the product as a white solid (460 mg, 1.06 mmol, 85%): MS m/e 434 (m+H)⁺.

Step 3


20



The Step 2 compound (95 mg, 0.22 mmol, 1 equiv) was dissolved in anhydrous CH₂Cl₂ (2.5 mL) under argon and cooled to -78°C. The mixture was treated with 25 diisopropylethylamine (65 µL, 0.37 mmol, 1.7 equiv), and triethylsilyl triflate (75 µL, 0.33 mmol, 1.5 equiv), and stirred at 0°C for 1.5 h. The reaction was mixed with MeOH (0.5 mL), silica gel (200 mg) and H₂O (2 drops) and stirred at rt for 18 h. The solvent was removed by 30 rotary evaporation and the residue purified flash column


chromatography on silica gel (2.5x10 cm) with 4% MeOH/CH₂Cl₂ to afford the product (92 mg, 0.17 mmol, 77%): MS m/e 548 (m+H)⁺.

5 Step 4



- The Step 3 compound (90 mg, 0.16 mmol, 1 equiv) was dissolved in anhydrous pyridine (2 mL) under argon and 10 cooled to -30°C. Treatment with imidazole (24 mg, 0.35 mmol, 2.1 equiv) and phosphorous oxychloride (66 μL, 0.67 mmol, 4.1 equiv), and continued stirring at -30°C for 45 min gave a thick slurry. Volatiles were by rotary evaporation and the cake dried further under reduced pressure. The product was purified by flash column chromatography on silica gel (2.5x10 cm) with 7% EtOAc/CH₂Cl₂ to afford the product as a white foam (76 mg, 87%): MS m/e 530 (m+H)⁺


20 Step 5



- The Step 4 compound (76 mg, 0.14 mmol) was dissolved in anhydrous CH₂Cl₂ (1 mL) and cooled to 0°C and treated with 25 TFA (1 mL) and H₂O (2 drops) and stirred for 1.5 hr at 0°C. The solvents were removed by rotary evaporation and the residue was chased with toluene (5 mL) and dried


under reduced pressure. Trituration with Et₂O afforded the title compound as a white solid (54 mg, 88%): MS m/e 316 (m+H)⁺.

5

Example 61


Step 1

10



An oven-dried flask purged with argon was charged with anhydrous CH₂Cl₂ (3 mL) and cooled to -78°C. Treatment with diethylaminosulfur trifluoride (DAST, 60 µL, 0.45 mmol, 1.5 equiv), followed by a solution of the Example 60 Step 2 compound (131 mg, 0.30 mmol, 1 equiv) in dry CH₂Cl₂ (3 mL). After 15 min, the reaction was poured into a separatory funnel containing satd aq NaHCO₃ (25 mL) and the layers were separated. The aqueous fraction was extracted with CH₂Cl₂ (25 mL), then the combined organic extracts were washed with brine (10 mL), dried (Na₂SO₄), filtered and concentrated. The product was purified by flash column chromatography on silica gel (2.5x10 cm) with 5% MeOH/CH₂Cl₂ to give Step 1 compound (124 mg, 0.29 mmol, 94%): MS m/e 436 (m+H)⁺.

Step 2




The fluorinated amide from Step 1 (161 mg, 0.37 mmol, 1 equiv) was dissolved in anhydrous pyridine (4 mL) under argon and cooled to -30°C. The mixture was treated with imidazole (54 mg, 0.77 mmol, 2.1 equiv) and phosphorous oxychloride (143 µL, 1.52 mmol, 4.1 equiv) and stirred at -30°C for 40 min. The solvent was removed by rotary evaporation and dried further under reduced pressure.


The product was purified by flash column chromatography on silica gel (2.5x10 cm) with 5% EtOAc/CH₂Cl₂ to give the Step 2 compound as a white foam (126 mg, 82%): MS m/e 418 (m+H)⁺.

15


Step 3



The Step 2 compound (125 mg, 0.30 mmol) was dissolved in TFA/CH₂Cl₂ (1:1 v/v, 2 mL), and stirred at rt. After 30 min, the solvents were removed by rotary evaporation, the remainder was chased with toluene (2x5 mL), and the solid dried under reduced pressure. Trituration with Et₂O afforded the title compound as a white solid (93 mg, 0.21 mmol, 72%): MS m/e 318 (m+H)⁺.

Example 62


Step 1




5

- The Step 1 compound was prepared beginning with 2-adamantanone and elaborated to the homochiral Boc-amino acid by an asymmetric Strecker synthesis according to
10 general method G.

Step 2



-
- 15 The title compound in Example 62 was prepared by the peptide coupling of the 2-adamantyl amino acid described in Step 1 followed by dehydration and deprotection as described in general method C. MS (M+H) 300.

Example 63

Step 1

5



An oven-dried flask equipped with a condenser and drying tube was charged with norbornane-2-carboxylic acid (4.92 g, 35 mmol, 1 equiv) and treated with bromine (2.1 mL, 41 mmol, 1.15 equiv) and phosphorous trichloride (0.153 mL, 1.8 mmol, 0.05 equiv). The mixture was heated at 85°C for 7 h protected from light. Additional bromine (0.4 mL, 7.8 mmol, 0.22 equiv) was added with continued heating for 1 h. The mixture was cooled to rt, and Et₂O (100 mL) was added. The mixture was washed with 10% aq NaHSO₃ (50 mL), H₂O (2x50 mL), and brine (25 mL). The ether fraction was dried (Na₂SO₄), filtered and concentrated by rotary evaporation. The product was purified by flash column chromatography on silica gel (5x15 cm) with 2% to 4% MeOH/CH₂Cl₂ + 0.5% HOAc. The product was chased with hexanes to remove residual HOAc. The isolated material consists of two inseparable materials (4.7 g), which was used without further purification in the next step.




25 The crude product from above, exo-2-bromonorbornane-1-carboxylic acid (4.7 g, impure) in Et₂O (80 mL) and MeOH (20 mL), was mixed with trimethylsilyldiazomethane (2.0 M in hexane, 11.8 mL, 23.6 mol), and stirred at rt for 1 h.

Solvent was removed by rotary evaporation, and purification of the oil by flash column chromatography on silica gel (5x18 cm) with a gradient of CH₂Cl₂/hexanes (600 mL each of 20% and 30%) followed by CH₂Cl₂ afforded 5 the product as a white solid (3.97 g, 0.017 mol, 79% for 2 steps): MS m/e 233/235 (m+H)⁺.




Methyl exo-2-bromonorbornane-1-carboxylate (2.0 g, 8.58 10 mmol, 1 equiv) was dissolved in anhydrous THF (50 mL) in an oven-dried 3-neck flask equipped with a condenser, and purged with argon. The mixture was treated with AIBN (288 mg, 1.71 mmol, 0.2 equiv) and tributyltin hydride (3.6 mL, 12.87 mmol, 1.5 equiv), and then heated to 15 reflux for 2 h. The flask was cooled to rt, and the THF was removed by rotary evaporation to give the crude product. The product was purified by flash column chromatography on silica gel (5x10 cm) with 5% EtOAc/hexanes. The resulting material was used in the 20 next step without further purification.

Step 2




25 The Step 1 compound was prepared beginning with 1-norbornyl methyl carboxylate and elaborated to the homochiral Boc amino acid by an asymmetric Strecker synthesis according to general method G.

Step 3




5 The title compound in Example 63 was prepared by the peptide coupling of the 1-norbonyl amino acid described in Step 2, followed by dehydration and deprotection as described in general method C. MS (M+H) 260.

Example 64


10

Step 1



15 The Step 1 compound was prepared beginning with 4-formylpyran and elaborated to the homochiral Boc amino acid by an asymmetric Strecker synthesis according to general method G.

20 Step 2




The title compound in Example 64 was prepared by the peptide coupling of the 4-pyranyl amino acid described in Step 2, followed by dehydration and deprotection as described in general method C. MS (M+H) 250.

5

General Method H: Strecker Synthesis of Racemic Amino Acids.


Scheme 10, General Method H, Examples 65-66

10



a. celite, PCC, CH_2Cl_2 , RT, 91% b. NH_4Cl , NaCN , MeOH ; 12M HCl , HOAc ; $(\text{Boc})_2\text{O}$, TEA, DMF.


Step 1



15


To a stirred solution of 1-phenylcyclo-1-pentane-carboxylic acid (5.00 g, 26.3 mmol) in 25 mL of THF at 0°C was added LAH (52 mL, 52 mmol, 1M) in THF. The reaction mixture was slowly warmed to rt and then refluxed for 18 h. The reaction was quenched according to the Fieser procedure: careful addition of 2 mL of water; 6 mL of 15% NaOH in water; and 2 mL of water. The biphasic mixture was diluted with 100 mL of ether and the granular white solid filtered off. The ether fraction was dried over Na_2SO_4 and evaporated to give 4.30 g (93%) of the Step 1 compound.

Step 2



- 5 To a stirred solution of Step 1 compound (0.80 g, 4.50 mmol) in 15 mL of CH₂Cl₂ at rt was added celite (5 g) followed by PCC (1.95 g, 5.00 mmol). After stirring for 3 h the reaction mixture was diluted with 40 mL of CH₂Cl₂ and filtered through celite. The filtrate was filtered
 10 an additional time through silica gel resulting in a colorless filtrate. The CH₂Cl₂ fraction was evaporated to give 0.72 g (91%) of the aldehyde as a colorless oil.


Step 3




- 15
- To a 50-mL round-bottomed flask containing Step 2 compound (0.72 g, 4.20 mmol) in 8 mL of water at rt was added NaCN (0.20 g, 4.20 mmol) followed by NH₄Cl (0.20 g, 5.00 mmol). To this reaction mixture was then added methanol (8 mL) and the mixture was allowed to stir overnight. The reaction mixture was then extracted with ether (2X15 mL), dried (MgSO₄) and concentrated under reduced pressure to give the crude Strecker product.
 20
 25 To a 100-mL round-bottomed flask containing the crude Strecker product was added 10 mL of HOAc and 10 mL of conc. HCl. The mixture was refluxed overnight. The mixture was concentrated under reduced pressure to give a

- yellow solid. The solid was triturated with 5 mL of 1:1 mixture of ether and hexanes. The white solid was treated with triethylamine (1.4 mL, 9.99 mmol) and di-tert-butyl dicarbonate (1.00 g, 4.60 mmol) in 50 mL DMF.
- 5 After 4 h the pH of the mixture was adjusted to 9 with saturated Na₂CO₃ soln. After an additional 3 h of stirring the mixture was extracted with 1:1 ether and hexanes and the aqueous fraction acidified to pH 2 with 5% KHSO₄ solution. The aqueous phase was washed with
- 10 ether (2 X 40 mL), the organics dried (MgSO₄), and evaporated to an oil that was purified by silica gel flash chromatography with 8:92 methanol:CH₂Cl₂ to give 0.3 g (23%) of the Boc-protected amino acid as a light oil (M-H, 318).

15

Example 65

Step 1




20

The synthesis of the Step 1 compound was described in general method H for the Strecker synthesis of racemic amino acids.


25

Step 2




The title compound in Example 65 was prepared by the
 5 peptide coupling of the cyclopentylphenyl amino acid described in Step 1 and general method H followed by dehydration and deprotection as described in general method C. MS (M+H) 310.

10

Example 66


Step 1

15



Step 1 compound was prepared using racemic Strecker synthesis according to general method H starting from 2,2-dimethyl-phenylacetic acid.


20 Step 2



The title compound in Example 66 was prepared by the peptide coupling of the dimethylphenyl amino acid described in step 1 followed by dehydration and deprotection as described in general method C. MS (M+H)

5 284.


Example 67



10 Step 1

N-(Benzylloxycarbonyl) succinimide (5.6 g, 22.4 mmol) was dissolved in CH₂Cl₂ (25 mL) and the solution was added to a cooled (0°C) and stirred solution of diethyl 15 aminomalonate hydrochloride (5.0 g, 23.6 mmol) and triethylamine (13.4 mL, 95 mmol) in CH₂Cl₂ (125 mL). The resulting solution was stirred at 0°C for 10 min and then at rt for 1 h. The solution was washed with 10% citric acid (2 x 50 mL), 10% sodium hydrogen carbonate (2 x 50 20 mL), and water (50 mL) and was then dried (Na₂SO₄) and evaporated to afford diethyl N-benzylloxycarbonylamino-malonate as a colorless oil, which crystallized upon standing at 0°C (6.3 g) (LC/Mass + ion):310 (M+H).

25 Step 2




Step 1 compound (6.18 g, 20 mmol) was dissolved in dry ethanol (30 mL) and added to a solution of sodium 30 ethoxide (2.85 g, 8.8 mmol; 21% w/w solution in ethanol (6 mL). A solution of 3-methyl-2-butenal (1.68 g, 20

- mmol) in ethanol (12 mL) was added, and the solution stirred at 25°C for 24 h. Acetic acid (0.56 mL) was then added the solution hydrogenated at 50 psi for 24 h using 10% Pd/C (2.0 g) as catalyst. The solution was filtered,
5 evaporated and the residue chromatographed on silica with CH₂Cl₂ / EtOAc (9:1) to give 2,2-dicarboethoxy-3,3-dimethyl-pyrrolidine (1.6 g) (LC/Mass, + ion): 244 (M+H).


10 This diester (850 mg) was refluxed in 5 M hydrochloric acid (10 mL)/TFA (1 mL) for 8 h to give, after evaporation, a powdery white solid. Crystallization from methanol/ether gave 3,3-dimethyl-dl-proline hydrochloride (190 mg) as white crystals mp 110-112°C.
15
Step 3
-
- Step 2 compound (173 mg, 0.97 mmol) was dissolved in DMF
20 (3 mL) / water (3 mL). To this clear solution was added triethylamine (0.46 mL, 3.18 mmol) and di-t-butyl dicarbonate (0.23 g, 1.06 mmol), and the reaction mixture was stirred at rt for 5 h. The solution was evaporated and the residue chromatographed on silica column using
25 CH₂Cl₂/methanol (9:1) as eluent to yield t-butyloxycarbonyl-3,3-dimethyl-dl-proline (200 mg) as an oil (LC/Mass, + ion): 244 (M+H).

Step 4




The title compound in Example 67 was prepared by the
 5 peptide coupling of the t-butyloxycarbonyl-3,3-dimethyl-
 dl-proline amino acid described in Step 3 followed by
 dehydration and deprotection as described in general
 method C. MS (M+H) 220.

10

Example 68

Step 1

15




20

Sodium ethoxide (940 mg of 21 wt% solution in ethanol,
 2.9 mmol) in ethanol (2 mL) was added to a stirred
 solution of diethyl acetamidomalonate (4.31g, 19.8 mmol)
 in EtOH (23 mL) at rt under argon. The reaction mixture
 was cooled to 0°C; and trans-2-pentenal (1.51 g, 18.0
 mmol) was added dropwise maintaining the reaction
 temperature at < 5°C. After the addition, the reaction
 was allowed to warm to rt, stirred for 4 h, then quenched
 with acetic acid (460 µl). The solution was concentrated
 25 in vacuo, and the residue dissolved in EtOAc (25 mL),
 washed with 10% NaHCO₃ solution (2x5 mL), brine and dried
 (MgSO₄). The solution was filtered and concentrated to a


10 mL volume, then heated to reflux and diluted with hexane (20 mL). Upon cooling to rt, the title compound precipitated and was collected to give 3.0 g (50%) of the Step 1 compound (mp 106-109°C; LC/Mass: + ions, 324
5 M+Na).

Step 2



10 To a solution of Step 1 compound (2.87 g, 9.5 mmol) and triethylsilane (2.28 mL, 14.3 mmol) in CH₂Cl₂ (30 mL) under argon was added TFA (7.35 mL, 95.3 mmol) dropwise with stirring while maintaining the internal temperature at 25°C by means of an ice bath. After stirring for 4 h
15 at rt, the solution was concentrated. The residue was diluted with CH₂Cl₂ (100 mL), then treated with H₂O (50 mL) and solid Na₂CO₃ with vigorous stirring until the mixture was basic. The organic layer was separated, dried (Na₂SO₄), filtered, then concentrated to give the
20 Step 2 compound as a yellow oil which was used without further purification (LC/Mass: + ions, 308 M+Na).

Step 3




25 Step 2 compound (3.73 g, 9.5 mmol) was suspended in 6 N HCl (20 mL) and HOAc (5 mL) and heated at reflux for 20 h. The reaction mixture was then cooled, washed with EtOAc (20 mL), then concentrated to give an oil which
30 crystallized upon trituration with ether to give the

title compound (1.2 g, 70.6%) (LC/Mass, + ion): 144 (M+H).

Step 4


5



Step 3 compound (692 mg, 3.76 mmol) was dissolved in acetone (12 mL)/ water (12 mL). To this clear solution was added triethylamine (1.9 mL, 12.8 mmol) and di-t-butyl dicarbonate (928 mg, 4.24 mmol). The reaction mixture was stirred at rt for 18 h. The solvents were evaporated and the residue chromatographed on silica with 1:9 methanol:CH₂Cl₂ to give the Step 4 compound as an oil (LC/Mass: + ions, 266 M+Na).

15


Step 5




Example 68 compound was prepared by peptide coupling of
20 Step 4 amino acid followed by dehydration and deprotection as described in general method C (MS (M+H) 234).

25

Example 69




Step 1



Sodium ethoxide (940 mg, 2.9 mmol; 21% w/w solution in
 5 ethanol) in ethanol (2 mL) was added to a stirred
 solution of diethyl acetamidomalonate (4.31 g, 19.8 mmol)
 in EtOH (23 mL) at rt under argon. The reaction mixture
 was cooled to 0°C; and 4-methyl-2-pentenal (1.77 g, 18.0
 mmol) was added dropwise maintaining the reaction
 10 temperature at < 5°C. After the addition, the reaction
 was allowed to warm to rt, stirred for 4 h, then quenched
 with acetic acid (460 µl). The solution was concentrated
 and the remainder dissolved in EtOAc (25 mL). The
 organics were washed with 10% NaHCO₃ solution (2x5 mL),
 15 brine and dried (MgSO₄). The solution was filtered and
 concentrated to 10 mL volume, then heated to reflux and
 treated with hexane (20 mL). On cooling, the Step 1
 compound precipitated and was collected (3.3 g) (LC/Mass,
 + ion): 338 (M+Na).

20

Step 2




25 To a solution of Step 1 compound (3.0g, 9.5 mmol) and
 triethylsilane (2.28 mL, 14.3 mmol) in CH₂Cl₂ (30 mL)
 under argon was added TFA (7.35 mL, 95.3 mmol) dropwise
 with stirring while maintaining the internal temperature
 at 25°C, by means of an ice bath. After stirring for 4 h

at rt, the solution was concentrated, the residue diluted with CH₂Cl₂ (100 mL), then treated with H₂O (50 mL) and solid Na₂CO₃ with vigorous stirring until the mixture was basic. The organic layer was separated, dried (Na₂SO₄), 5 filtered, then concentrated to give the title compound as an oil which was used without further purification (LC/Mass: + ions, 300 M+H).


Step 3

10




20 Step 4

Step 2 compound (3.8 g, 9.5 mmol) was suspended in 6 N HCl (20 mL) and HOAc (5 mL) and heated at reflux for 20 h. The reaction mixture was cooled, washed with EtOAc (20 mL), then concentrated to give an oil which crystallized upon trituration with ether to give the step 15 3 compound (1.4 g, 76.0%). LC/Mass: + ions, 158 (M+H).




Step 3 compound (728 mg, 3.76 mmol) was dissolved in a 25 1:1 acetone/water solution (24 mL). To this clear solution was added triethylamine (1.9 mL, 12.8 mmol) and di-t-butyl dicarbonate (928 mg, 4.24 mmol). The reaction mixture was stirred at rt for 18 h. The solution was evaporated and the residue chromatographed on silica 30 column using CH₂Cl₂/ methanol (9:1) as eluent to give the title compound as an oil (LC/Mass, + ion): 258 (M+H).

Step 5




- 5 Example 69 compound was prepared by peptide coupling of Step 4 amino acid followed by dehydration and deprotection as described in general method C (MS: (M+H) 248).

10

Example 70


Step 1

15



- Step 1 compound was prepared by the procedure described in General Method C starting from N-Boc-S-t-butylcysteine.

Step 2




25

- A 25-mL round-bottomed flask equipped with a magnetic stirring bar and N₂ inlet was charged with Step 1 compound


(78 mg, 0.21 mmol) and chloroform (3 mL). The mixture was cooled to 0°C and treated with *m*-chloroperoxybenzoic acid (85 mg, 0.44 mmol) in CHCl₃ (2 mL). After 3 h the solution was diluted with CHCl₃ (7 mL), washed with 5% NaHCO₃ (2x5 mL), H₂O and dried over Na₂SO₄. Removal of solvent gave crude sulfoxide (100 mg), which was used without further purification (LC/Mass, + ions): 384 (M+H).

10 Step 3




15 Trifluoroacetic acid (1.5 mL) was added to a cooled (0°C) solution of Step 2 compound (100 mg, 0.26 mmol) in 5 mL CH₂Cl₂. The solution was then stirred at 0°C for 1.5 h, diluted with CH₂Cl₂ (5 mL) and concentrated under reduced pressure to a thick oil. The product was purified by
20 reverse phase preparative column chromatography on a YMC S5 ODS 20x100 mm column to give the title compound of Example 70 , 17 mg, 16%. Purification conditions: gradient elution from 10% methanol/water/0.1 TFA to 90% methanol/water/ 0.1 TFA over 15 min 5 min hold at 90%
25 methanol/water/0.1 TFA. Flow rate: 20 mL/min. Detection wavelength: 220. Retention Time 10 Min (LC/Mass, + ion): 284 (M+H).

Example 71



30


Step 1



- 5 A 25-mL round-bottomed flask equipped with a magnetic stirring bar and N₂ inlet was charged with compound from Example 70, Step 1 (78 mg, 0.21 mmol) in chloroform (3 mL). The mixture was cooled to 0°C and treated with *m*-chloroperoxybenzoic acid (144 mg, 0.84 mmol) in CHCl₃ (2 mL). After 30 min at rt, the solution was diluted with CHCl₃ (7 mL), washed with 5% NaHCO₃ (2x10 mL), H₂O and dried over Na₂SO₄. Removal of solvent gave the crude sulfone (100 mg), which was used without further purification (LC/Mass, + ion): 344 (M+H-Bu).
- 10

15

Step 2



- 20 Trifluoroacetic acid (1.5 mL) was added to a cooled (0°C) and stirred solution of Step 1 compound (100 mg, 0.26 mmol) in 5 mL CH₂Cl₂. The solution was stirred at 0°C for 30 min, diluted with CH₂Cl₂ (5 mL) and concentrated under reduced pressure to a thick oil. The product was
- 25 purified by reverse phase preparative column chromatography on a YMC S5 ODS 20x100 mm column to give the title compound, 14 mg, 17%. Purification conditions: gradient elution from 10% methanol/water/0.1 TFA to 90% methanol/water/ 0.1 TFA over 15 min. 5 min hold at 90%
- 30 methanol/water/0.1 TFA. Flow rate:20 mL/min. Detection

wavelength: 220. Retention Time 10 Min. (LC/Mass, + ion): 300 (M+H).

Example 72


5



- The title compound was prepared following a published procedure (Sasaki et al, Tetrahedron Lett. 1995, 36, 10 3149, Sasaki et al. Tetrahedron 1994, 50, 7093) used to synthesize (2S,3R,4S)-N-Boc-3,4-methano-L-proline carboxylate. The corresponding amide was prepared by general method A and deprotected with TFA to give the TFA salt also as described in general method A.


15

Example 73




- 20 The title compound was prepared by coupling (2S,3R,4S)-3,4-methano-L-proline carboxamide-N-trifluoroacetate described in Example 72 with L-cyclohexylglycine and then dehydrated to the amide with POCl₃/imidazole and deprotected (N-terminal nitrogen) with TFA using general
25 C (FAB MH⁺ 248).

Example 74




The title compound was prepared by coupling (2S,3R,4S)-3,4-methano-L-proline carboxamide-N-trifluoroacetate described in Example 72 with L-tert-butylglycine and then 5 dehydrated to the amide with POCl₃/imidazole and deprotected (N-terminal nitrogen) with TFA using general C (FAB MH⁺ 222).


10

Example 75


20

Example 76

The title compound was prepared by coupling (2S,3R,4S)-3,4-methano-L-proline carboxamide-N-trifluoroacetate described in Example 72 with N-(tert-butyloxycarbonyl)-(1'ethylcyclopentyl)glycine described in General Method B and then dehydrated to the amide with POCl₃/imidazole and deprotected (N-terminal nitrogen) with TFA using general 25 C (FAB MH⁺ 262).

Example 77


- 5 The title compound was prepared by coupling (2S,3R,4S)-
3,4-methano-L-proline carboxamide-N-trifluoroacetate
described in Example 72 with N-(tert-butyloxycarbonyl)-
(1' vinylcyclopentyl)glycine described in General Method B
and then dehydrated to the amide with POCl₃/imidazole and
10 deprotected (N-terminal nitrogen) with TFA using General
Method C (FAB MH⁺ 260).

Example 78

15


- N-[((S)-cyclopentylvinyl)-N-tert-butoxycarbonylglycyl]-
(2S,4S,5S)-2-cyano-4,5-methano-L-prolylamide (70 mg, 0.19
mmol) described in General Method C, Step 2 was dissolved
20 in a mixture of 2 mL *t*-BuOH / 3 mL THF and N-
methylmorpholine-N-oxide (33mg, 0.28 mmol) was added
followed by osmium tetroxide (0.1 mmol, 50 mol%). The
reaction was quenched with 1 mL of 10% aqueous Na₂SO₃ and
was taken up in EtOAc and washed with H₂O 5 mL, dried
25 (Na₂SO₄), filtered, evaporated and purified by silica gel
flash chromatography (5% MeOH/CH₂Cl₂) to give 41 mg (55%)
of the protected diol as an oil. The title compound was
obtained by deprotection of the amine functionality with
TFA according to General Method C (FAB MH⁺ 294).

30

Example 79

5 **General Procedure I:** Synthesis of Quaternary Amino Acids
 Via Michael Addition to Malonates followed by Selective
 Hydrolysis and Curtius Rearrangement. Examples 79-84.


10 Cyclohexanone and diethylmalonate underwent Knoevenagel
 condensation mediated by titanium tetrachloride in THF
 and CCl₄ to give 40. Copper (I) mediated Grignard
 addition of methylmagnesium bromide gave 41 which was
 selectively saponified to 42. Curtius rearrangement with
 trapping by benzyl alcohol gave 43 which was converted to
 15 44 by a standard deprotection-protection protocol. Ester
 44 was saponified to give the quaternary amino acid 45.

Scheme 11, General Method I

a. THF, CCl₄, TiCl₄, diethylmalonate, 0 C; pyridine, THF, 0 to RT 72 h b. MeMgBr,
 CuI, Et₂O, 0 C c. 1N NaOH, EtOH, RT 6 days d. Ph₂PON₃, TEA, RT to reflux to RT,
 BnOH e. 10% Pd(OH)₂/C, EtOAc; (Boc)₂O, K₂CO₃, THF f. IN NaOH, dioxane

20

Step 1




5

According to literature procedure (Tetrahedron 1973, 29, 435), a mixture of dry tetrahydrofuran (400 mL) and dry carbon tetrachloride (50 mL) was cooled to 0°C (ice-salt bath) and treated with titanium tetrachloride (22.0 mL, 0.2 mole). The resulting yellow suspension was stirred at 0°C for 5 min, treated sequentially with cyclohexanone (10.3 mL, 0.1 mole) and distilled diethylmalonate (15.2 mL, 0.1 mole) then stirred at 0°C for 30 min. The reaction mixture was then treated with a solution of dry pyridine (32 mL, 0.40 mole) in dry THF (60 mL), stirred at 0°C for 1.0 h, then at rt for 72 h. The reaction mixture was quenched with water (100 mL), stirred for 5 min then extracted with ether (2 x 200 mL). The combined organic extracts were washed with saturated sodium chloride (100 mL), saturated sodium bicarbonate (100 mL) and brine (100 mL), dried over anhydrous magnesium sulfate, filtered and concentrated. Flash chromatography using 5% EtOAc in hexane gave step 1 compound as a light-yellow oil. Yield: 5.25 g (22%). MS (M + Na) 263.


25

Step 2



5 According to literature (Org. Syn. VI, 442, 1988; Liebigs Ann. Chem. 1981, 748) a mixture of 3.0 M methylmagnesium iodide (3.1 mL, 9.36 mmol) and cuprous chloride (9.0 mg) was stirred at 0°C (ice-salt water bath), treated with a solution of Step 1 compound (1.5 g, 6.24 mmol) in dry
 10 ether (1.8 mL) over 5 min and stirred at 0°C for 1 h, then at rt for 40 min. The mixture was slowly added to a slurry of ice and water (15 mL), treated dropwise with 10% HCl (3.7 mL) then extracted with EtOAc (3 x 25 mL). The combined organic extracts were washed with 1% sodium
 15 thiosulfate (2.0 mL) and saturated sodium chloride (2.0 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated. Flash chromatography on a silica gel column using 5% ether in hexane (1.0 L) gave step 2 compound as a clear syrup. Yield: 1.09 g, (68%). MS
 20 (M+H) 257.

Step 3



25


A solution of Step 2 compound (1.09 g, 4.03 mmol) in a mixture of methanol (5.4 mL) and water (2.7 mL) was treated with 1N sodium hydroxide (4.84 mL, 4.84 mmol) or

1.2 equiv) and stirred at rt for 6 days. The reaction mixture still showed the presence of starting material, so THF (4.0 mL) was added and the entire mixture stirred for another 2 days. The solution was evaporated to dryness and the resulting syrup partitioned between water (8.0 mL) and ether (15 mL). The aqueous phase was acidified with 1N hydrochloric acid (4.8 mL) to pH 2-3 and extracted with EtOAc (3 x 25 mL). The combined organic extracts were washed with brine (10.0 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated to give step 3 compound as a thick syrup.

Yield: 875 mg, (95.1%). MS (M + H) 229.

Or alternately: solutions of the diester in a mixture of ethanol, THF, dioxane and water or mixtures thereof may be hydrolyzed with sodium hydroxide.

Step 4




20

According to literature (J. Org. Chem 1994, 59, 8215), a solution of Step 3 compound (0.875 g, 3.83 mmol) in dry benzene (4.0 mL) was treated with triethylamine (0.52 mL, 3.83 mmol) and diphenylphosphoryl azide (0.85 mL, 3.83 mmol), refluxed under nitrogen for 1 h and cooled to rt. The solution was treated with benzyl alcohol (0.60 mL, 5.75 mmol or 1.5 equiv), refluxed for 17 h, cooled then diluted with ether (40 mL). The solution was washed with 10% aqueous citric acid (2x3 mL), back-extracting the citric acid wash with ether (40 mL). The combined

organic extracts were washed with 5% sodium bicarbonate (2x3 mL), dried ($MgSO_4$), filtered, and concentrated. Flash chromatography on silica gel of the crude product with 10% EtOAc in hexane (1.0 L) gave step 4 compound as
 5 a clear thick syrup. Yield: 1.15 g (90%). MS($M+H$) 334.

Step 5



10

A solution of Step 4 compound (1.15 g, 3.46 mmol) in EtOAc (60 mL) was treated with palladium hydroxide on carbon (298 mg) and hydrogenated at rt for 20 h. The mixture was filtered through a celite pad and then
 15 washing the pad well with EtOAc (3 x 25 mL) then the filtrate was concentrated to give the free amine. A solution of the amine in tetrahydrofuran (12 mL) and water (12 mL) was treated with di-*t*-butyl dicarbonate (1.0 g, 4.58 mmol or 1.48 equiv) and potassium carbonate (854 mg, 6.18 mmol or 2.0 equiv), then stirred at rt for
 20 20 h. The reaction mixture was partitioned between water (8 mL) and diethyl ether (3 x 40 mL) and the combined organic extracts were washed with brine (8 mL), dried ($MgSO_4$), filtered, and concentrated. Flash chromatography
 25 of the crude product with 10% EtOAc in hexane (1 L) gave step 5 compound as a clear thick syrup. Yield: 1.18 g (100%). MS: ($M+H$) 300.

Other methods can also be employed, for example:

30 According to Tetrahedron Lett. 1988, 29, 2983, where a solution of the benzylcarbamate in ethanol may be treated


with triethylsilane (2 equiv), di-*t*-butyldicarbonate (1.1 equiv), catalytic palladium acetate and triethylamine (0.3 equiv) to give the BOC-protected amine in a "one-pot" manner.

5

Or alternately: Solutions of the benzylcarbamate in methanol may be subjected to hydrogenolysis in the present of di-*t*-butyldicarbonate to give the BOC-protected amine in a "one-pot" manner.


10

Step 6



- 15 A solution of Step 5 compound (1.18 g, 3.09 mmol) in dioxane (8.0 mL) was treated with 1N sodium hydroxide (9.1 mL, 9.1 mmol or 3.0 equiv) and stirred at 60°C (oil bath) for 28 h. The reaction mixture was concentrated to a syrup which was dissolved in water (15 mL) and
20 extracted with ether (25 mL). The aqueous phase was acidified to pH 2-3 with 1N hydrochloric acid (9.2 mL) then extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with saturated sodium chloride (10 mL), dried (MgSO_4), filtered, and
25 concentrated to give Step 6 compound as an off-white solid. Yield: 808 mg (96%). MS ($\text{M}+\text{H}$) 272.

Step 7




5 The title compound was prepared from Step 6 compound according to the procedure in General Method C where the amino acid was coupled, the amide was dehydrated, and the protecting group removed to give the title compound. MS (M+H) 262.

10


Compounds 90-100 were prepared by General Method I and General Method C starting from cyclohexanone, cyclopentanone and cyclobutanone, and employing methyl-, ethyl-, allyl- and propylmagnesium halides as Grignard reagents.

15


Table 5

Example #	Cycloalkane	R	MS Data M+H
79	cyclohexane	Methyl	262
80	cyclohexane	Ethyl	276
81	cyclopentane	Methyl	248
82	cyclopentane	Allyl	274
83	cyclopentane	Propyl	276
84	cyclobutane	Methyl	234

20

Example 85


Step 1



According to Example 79: A mixture of dry carbon tetrachloride (50 mL) was cooled to 0°C (ice-salt bath) 10 and treated with titanium tetrachloride (11.0 mL, 0.1 mol). The resulting yellow suspension was stirred at 0°C for 5 min, treated sequentially with cyclopentanone (4.42 mL, 0.05 mol) and distilled diethylmalonate (7.6 mL, 0.05 mol) then stirred at 0°C for 30 min. The reaction mixture 15 was then treated with a solution of dry pyridine (16 mL, 0.20 mol) in dry THF (30 mL), stirred at 0°C for 1.0 h, then at rt for 20 h. The reaction mixture was quenched with water (50 mL), stirred for 5 min then extracted with ether (2 x 100 mL). The combined organic extracts were 20 washed with saturated sodium chloride (50 mL), saturated sodium bicarbonate (50 mL) and brine (50 mL), dried ($MgSO_4$), filtered and concentrated. Flash chromatography using 5% EtOAc in hexane gave Step 1 compound as a light yellow oil. Yield: 7.67 g (68%). MS (M + H) 226.


25

Step 2



- 5 A solution of Step 1 compound (1.00 g, 4.42 mmol) in methanol (50 mL) was treated with 10% Pd/C (0.20 g, 10 mol%) and hydrogenated (balloon pressure) at rt for 20 h. The mixture was diluted with methanol and filtered through a pad of celite. The filtrate was concentrated
10 and purified by flash column chromatography on silica gel with 7% EtOAc in hexanes to give 0.84 g (91%) of Step 2 compound. MS (M+H) 229.


Step 3



15

- The Step 3 compound was prepared by the process outlined in General Method H, where the ester underwent
20 hydrolysis, Curtius Rearrangement, protecting group exchange, and again final ester hydrolysis.

Step 4




25

The title compound was prepared from Step 3 compound according to the procedure in General Method C where the amino acid was coupled, the amide was dehydrated, and the protecting group removed to give the title compound. MS 5 (M+H) 234.

Examples 86 and 87 were prepared by the procedures used for Example 85 starting from cyclohexanone and cyclobutanone respectively.


10




Example #	Cycloalkane	Mass Spec	
			M+H
85	cyclopentyl	234	
86	cyclohexyl	248	
87	cyclobutyl	220	

Example 89

15




Step 1



Step 1 compound was prepared in Example 6 Step 1.

Step 2


5






The title compound was prepared from Step 1 compound according to General Method C, where the carboxylic acid
10 underwents a peptide coupling, the amide dehydration and protecting group removal. MS (M+H) 218.

Examples 90 to 99


Examples of compounds where X = H include the following compounds which may be prepared employing procedures as described hereinbefore.



Ex. #	n	x	y	R ¹	R ²	R ³	R ⁴
90	0	0	1	t-Bu	H	H	-
91	0	0	1	adamantyl	H	H	-
92	0	0	1		H	H	-
93	0	0	1		H	Me	-
94	0	1	0	t-Bu	H	H	-
95	0	1	0	adamantyl	H	H	-
96	0	1	0		H	H	-
97	0	1	0		H	Me	-
98	1	0	1	H	H	H	t-Bu
99	1	1	0	Me	H	H	t-Bu

Examples 100 to 109


Examples of compounds where n = 1 include the following compounds which may be prepared employing procedures as
5 described hereinbefore.



Ex. #	X	x	y	R ¹	R ²	R ³	R ⁴
100	CN	0	1	H	H	H	t-Bu
101	CN	0	1	H	H	H	adamantyl
102	CN	0	1	H	Me	H	
103	CN	0	1		H	Me	H
104	CN	1	0	t-Bu	H	H	H
105	CN	1	0	adamantyl	H	H	Me
106	CN	1	0		Et	H	H
107	CN	1	0	H	H	Me	
108	H	0	1	t-Bu	H	H	H
109	H	1	0	Me	H	H	t-Bu

What is Claimed is:

1. A compound having the structure



5

herein x is 0 or 1 and y is 0 or 1, provided that

x = 1 when y = 0 and

x = 0 when y = 1; and wherein

n is 0 or 1;

10


X is H or CN;

R¹, R², R³ and R⁴ are the same or different and are independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, bicycloalkyl, tricycloalkyl, alkylcycloalkyl, hydroxyalkyl,


15 hydroxyalkylcycloalkyl, hydroxycycloalkyl, hydroxybicycloalkyl, hydroxytricycloalkyl, bicycloalkylalkyl, alkylthioalkyl, arylalkylthioalkyl, cycloalkenyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl or cycloheteroalkylalkyl; all optionally substituted through available carbon atoms with 1, 2, 3, 4 or 5 groups selected from hydrogen, halo, alkyl, polyhaloalkyl, alkoxy, haloalkoxy, polyhaloalkoxy, alkoxy carbonyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, polycycloalkyl, heteroaryl amino, 20 aryl amino, cycloheteroalkyl, cycloheteroalkylalkyl, hydroxy, hydroxyalkyl, nitro, cyano, amino, substituted amino, alkyl amino, dialkyl amino, thiol, alkylthio, alkyl carbonyl, acyl, alkoxy carbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, 25 arylamino, cycloheteroalkyl, cycloheteroalkylalkyl, hydroxy, hydroxyalkyl, nitro, cyano, amino, substituted amino, alkyl amino, dialkyl amino, thiol, alkylthio, alkyl carbonyl, acyl, alkoxy carbonyl, aminocarbonyl, alkynylaminocarbonyl, alkylaminocarbonyl, 30 alkenylaminocarbonyl, alkylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, alkylsulfonylamino, alkylaminocarbonylamino, alkoxy carbonylamino, alkylsulfonyl, aminosulfinyl, aminosulfonyl, alkylsulfinyl, sulfonamido or sulfonyl;

- and R¹ and R³ may optionally be taken together to form -(CR⁵R⁶)_m- where m is 2 to 6, and R⁵ and R⁶ are the same or different and are independently selected from hydroxy, alkoxy, H, alkyl, alkenyl, alkynyl, cycloalkyl,
- 5 halo, amino, substituted amino, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino,
- 10 alkoxycarbonyl, aryloxycarbonyl, or alkylaminocarbonylamino, or R¹ and R⁴ may optionally be taken together to form -(CR⁷R⁸)_p- wherein p is 2 to 6, and R⁷ and R⁸ are the same or different and are independently selected from hydroxy, alkoxy, cyano, H, alkyl, alkenyl,
- 15 alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, halo, amino, substituted amino, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, alkylcarbonylamino, arylcarbonylamino, alkoxycarbonylamino, aryloxycarbonylamino,
- 20 alkoxycarbonyl, aryloxycarbonyl, or alkylaminocarbonylamino, or optionally R¹ and R³ together with
-
- R⁴ from a 5 to 7 membered ring containing a total of 2 to 4 heteroatoms selected from N, O, S, SO, or SO₂;
- 25 or optionally R¹ and R³ together with
-
- form a 4 to 8 membered cycloheteroalkyl ring wherein the cycloheteroalkyl ring has an optional aryl ring fused thereto or an optional 3 to 7 membered cycloalkyl ring fused thereto;
- 30 including all stereoisomers thereof;
and a pharmaceutically acceptable salt thereof, or a prodrug ester thereof, and all stereoisomers thereof.


2. The compound as defined in Claim 1 having the structure:




5 3. The compound as defined in Claim 1 having the structure:



10 4. The compound as defined in Claim 1 having the structure:




5. The compound as defined in Claim 1 having the
15 structure:




6. The compound as defined in Claim 1 wherein:
20 R³ is H, R¹ is H, alkyl, cycloalkyl, bicycloalkyl,
tricycloalkyl, alkylcycloalkyl, hydroxyalkyl,
hydroxyalkylcycloalkyl, hydroxycycloalkyl
hydroxybicycloalkyl, or hydroxytricycloalkyl,
R² is H or alkyl, n is 0,
25 X is CN.

7. The compound as defined in Claim 1 wherein the cyclopropyl fused to the pyrrolidine has the configuration:



5

8. The compound as defined in Claim 1 having the structure:




15

or a pharmaceutically acceptable salt thereof.

9. The compound as defined in Claim 8 wherein the pharmaceutically acceptable salt is the hydrochloride salt or the trifluoroacetic acid salt.


10. The compound as defined in Claim 1 which is



A

(1S,2(2S),3S,5S)

wherein R¹ is alkyl, cycloalkyl, bicycloalkyl,
5 tricycloalkyl, alkylcycloalkyl, hydroxyalkyl,
hydroxycycloalkyl, hydroxyalkylcycloalkyl,
hydroxybicycloalkyl, or hydroxytricycloalkyl,
or



B

10 (1R,2S,3(2S),5S)

wherein R¹ is alkyl, cycloalkyl, bicycloalkyl,
tricycloalkyl, alkylcycloalkyl, hydroxyalkyl,
hydroxycycloalkyl, hydroxyalkylcycloalkyl,
hydroxybicycloalkyl, or hydroxytricycloalkyl.

15

11. A pharmaceutical composition comprising a compound as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.

20

12. A pharmaceutical combination comprising a DP4 inhibitor compound as defined in Claim 1 and an antidiabetic agent other than a DP4 inhibitor for treating diabetes and related diseases, an anti-obesity agent and/or a lipid-modulating agent.

25

13. The pharmaceutical combination as defined in Claim 12 comprising said DP4 inhibitor compound and an antidiabetic agent.

14. The combination as defined in Claim 13 wherein
the antidiabetic agent is 1, 2, 3 or more of a biguanide,
a sulfonyl urea, a glucosidase inhibitor, a PPAR γ
5 agonist, a PPAR α/γ dual agonist, an SGLT2 inhibitor, an
aP2 inhibitor, a glycogen phosphorylase inhibitor, an AGE
inhibitor, an insulin sensitizer, a glucagon-like
peptide-1 (GLP-1) or mimetic thereof, insulin and/or a
meglitinide.

10

15. The combination as defined in Claim 14 wherein
the antidiabetic agent is 1, 2, 3 or more of metformin,
glyburide, glimepiride, glipizide, glipizide,
chlorpropamide, gliclazide, acarbose, miglitol,
pioglitazone, troglitazone, rosiglitazone, insulin, Gl-
262570, isaglitazone, JTT-501, NN-2344, L895645, YM-440,
R-119702, AJ9677, repaglinide, nateglinide, KAD1129, AR-
HO39242, GW-409544, KRP297, AC2993, Exendin-4, LY307161,
NN2211, and/or LY315902.

20

16. The combination as defined in Claim 13 wherein
the compound is present in a weight ratio to the
antidiabetic agent within the range from about 0.01 to
about 100:1.

25

17. The combination as defined in Claim 12 wherein
the anti-obesity agent is a beta 3 adrenergic agonist, a
lipase inhibitor, a serotonin (and dopamine) reuptake
inhibitor, a thyroid receptor beta compound, an anorectic
30 agent, and/or a fatty acid oxidation upregulator.

18. The combination as defined in Claim 17 wherein
the anti-obesity agent is orlistat, ATL-962, AJ9677,
L750355, CP331648, sibutramine, topiramate, axokine,
35 dexamphetamine, phentermine, phenylpropanolamine,
famoxin, and/or mazindol.

19. The combination as defined in Claim 12 wherein
the lipid modulating agent is an MTP inhibitor, an HMG
CoA reductase inhibitor, a squalene synthetase inhibitor,
a fibric acid derivative, an upregulator of LDL receptor
5 activity, a lipoxygenase inhibitor, an ACAT inhibitor, a
cholesteryl ester transfer protein inhibitor, or an ATP
citrate lyase inhibitor.

20. The combination as defined in Claim 19 wherein
10 the lipid modulating agent is pravastatin, lovastatin,
simvastatin, atorvastatin, cerivastatin, fluvastatin,
nisvastatin, visastatin, fenofibrate, gemfibrozil,
clofibrate, implitapide, CP-529,414, avasimibe, TS-962,
MD-700, and/or LY295427.

15

21. The combination as defined in Claim 19 wherein
the DP4 inhibitor is present in a weight ratio to the
lipid-modulating agent within the range from about 0.01
to about 100:1.

20

22. A pharmaceutical combination comprising a DP4
inhibitor compound as defined in Claim 1 and an agent for
treating infertility, an agent for treating polycystic
ovary syndrome, an agent for treating a growth disorder
25 and/or frailty, an anti-arthritis agent, an agent for
preventing inhibiting allograft rejection in
transplantation, an agent for treating autoimmune
disease, an anti-AIDS agent, an agent for treating
inflammatory bowel disease/syndrome, an agent for
30 treating anorexia nervosa, an anti-osteoporosis agent
and/or an anti-obesity agent.

23. A method for treating diabetes, insulin
resistance, hyperglycemia, hyperinsulinemia, or elevated
35 blood levels of free fatty acids or glycerol, obesity,
Syndrome X, dysmetabolic syndrome, diabetic
complications, hypertriglyceridemia,

- hyperinsulinemia, atherosclerosis, impaired glucose homeostasis, impaired glucose tolerance, infertility, polycystic ovary syndrome, growth disorders, frailty, arthritis, allograft rejection in transplantation,
- 5 autoimmune diseases, AIDS, intestinal diseases, inflammatory bowel syndrome, nervosa, osteoporosis, or an immunomodulatory disease or a chronic inflammatory bowel disease, which comprises administering to a mammalian species in need of treatment a therapeutically effective
- 10 amount of a compound as defined in Claim 1.

24. The method as defined in Claim 23 for treating type II diabetes and/or obesity.

15

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.